
<link rel="stylesheet" href="https://bootswatch.com/4/flatly/bootstrap.min.css"><link rel="stylesheet" href="style.css"><script src="https://ajax.googleapis.com/ajax/libs/jquery/3.5.1/jquery.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.16.0/umd/popper.min.js"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.5.2/js/bootstrap.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1">
<div class="header"><div class="top_text"><p id="home">03/14/23</p><p class="summary"><strong> <em>Summary: New data in 3 studies; Expedited timeline in 8 studies; 11 new studies; 1 new IND acceptance.</em> </strong></p></div><div id="images" class="logos"><img src="data:image/png;base64,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" alt="Lexidyne Logo" width="150" class="lex"><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAbgAAAC8CAYAAAAKLLsRAAAABGdBTUEAALGPC/xhBQAAACBjSFJNAAB6JgAAgIQAAPoAAACA6AAAdTAAAOpgAAA6mAAAF3CculE8AAAABmJLR0QA/wD/AP+gvaeTAAAp5ElEQVR42u2deZwU1bXHv6d6hhl2EFTcxRVwNyYxGhXUGEHBKE53D4jLS5REjZj4nlk1k7ws6nONO27EhenuUVbFHdC4xQ0VQYyIC4iyDgwwa1ed90dPUBG6umd6nTnfz2c+MD23q26dOnV/99y691wwDMMoVmbUHsfU2j5mCGNrOGYCwzCKFqWOgM5mSl0/M4ZhAmcYRsehqc87wD6UxJ/lsdo9zCCGCZxhGB2DoLjAo8AhuPoGM9ecZEYxTOAMw+gYiExs/V8/VGYxfe3lqIoZxjAnMAyjuFEVZqxbhOh+X37GP/Gc8zi9z4dmIIvgDMMwijWCU/Cu3qLrfgwB701mrL2QmAbMSCZwhmEYxcm87SYB87b4tBdwK2W1rzNtzVFmpE7Y9zETGIbRIZixdjgwaxt/VUQexon/nlO2/7cZywTOMAyj2EQuAoSSlIgD9xKQv3JK30/MYCZwhmEYxcHU2j4E9G1gd5+SHjALx6ni1D5vmOFM4AzDMAqfaatPxHGeSrF9U+AxVG9l3nZPUSWeGdAEzjAMo3CZsfZ3wJ/T+o6yDPQeSrvcyoieq8yIJnCGYRiFycw1k1A5pw3fbAJ9DHUeote6WQwb2GjGNIEzDMMoHGLahfLap4Dj2nGUdYhMAZlMj97PMUziZlgTOMMwjPzz5BfdaeoyCzg2A0erRfUZVB9FAzM4ve86M7AJnGEYRv6YtaYXcXkC+F67j6Xa+kML6HOo9yTqzGZ+/7dsgooJnGEYRr5E7jHg+xkSuK/8X0FZi+pzeMzB09lUDliYSCFmmMAZhmFkXeS0jHjtvcCYLAjcFr9rHTAfjzdAX0Can2fMXivsJpjAGYZhZAdV4dHav6D8JssCt7UyH6P6KqrvICykJT6fZXsvsaFNEzjDMIzMMb32HERvB7rmUOC29nsDqgtRfRe8BXjOB4j3MU7Lp/zkgLV2o0zgDMMw0mfa2oNwiAGD8ihwyT5rRPkc1eUoy1Hvc9DluLoKpRahFk9qaZFaJFDLrwZtsJtqAmcYhpEgtrIHZSV3IIwtQIFLt0wc1VqU2tZ/N6DeOjyNI9ThahNQj3ob8WgBL5GRU7xavM3X14zKatRdQbnOp2pYUS9yN4EzDMOYuXYMyk1A/yIWuMwd11NQGvH0ZfDuo7kpxs0jmortttqGp4ZhGCO3m0y89ABEaswYmylHGAZyP6VlS7j02UqL4AzDMIqZ6bVnIHoDW9typ3NFcN/8u6dT8ZrP5eYRdRbBGYZhFBun9Z2CNA5GpAqoN4N8LSQ6Haf0FS5+ameL4AzDMIqZaWt2w5GrgDDgdPoI7svfP0CcY7jpxIJevG4RnGEYxrb4Ub+ljNpuLB6Hgk4h0cwbsC+eO41z55SbwBmGYRS10G03n1H9RuM4hwHTTOgAOJIezdcVcgVtiNIwDCNdHl49CEcnoDoO1e6dcIjyP58pnpzMbSc9ZQJnGIbRkXh0XV+ams7H4yJUd++EAgeqi2jpfzATj2gptNtjQ5SGYRht5dQ+tYze8RoW7DAQnGNQmQhs7GRWGETJqostgjMMw+joTF/Vk/qm0aiEUB2GalkHj+BAtRbKd+e2YQUl7hbBGYZhZJLTtt9A5a6TGLPLcDY62+E4oxB5AFjXga+6L9rwE4vgDMMwOiNztISly76F5x2HuseicgyqvTpIBAeqH7Pjq3tTVVUw+9uZwBmGYeSDmAao++RgxDsczzsE9BA8DkG1d5EKHCgncMeI2YVi4hLzMsMwjDwQFBeY1/rzJXd+uDueNxD19gAGgu4J/Odn18Jut6USMIEzDMMwtsL4vT8FPt3q36rmlNB7wK5oyx4J4ZMBqPYH+m3jJ9PzLFqAWoQVKJ8BK4DPgCXAYuLNiwpKbs2bDMMwOiCqwh/f6EeZ9kK9EuLaEwBPeoPngJbj0RXX/cp3ZCNeSwvxzR9sQGU9bmA99evXM3GkJZ82DMMwDMMwDMMwDMMwDMMwDMMwDMMwDMMwDMMwDMMwDMMwDMMwDMMwjAxhC70NwzAKkfs+Kqe+aSpoCZ7notQldtDWdYkCXi2eB8o6FEW9OlAXVzaAF0d1Ey7NiNbjeU14NECgkZKWJja69cR7NXPtIZtM4AzDMIzcc8uiS0BvynKy5RZUN6K4qNah6uGxPqGhXm1r8uU6wEW9RqABTz20tYzqBlw3DjSB1KOqeF5ChNXbiOu1INJM3EuIacCrBaChZBOysZmW0hZqglnZR84EzjAMo1CpmlNC/wFvoXpAkewm0L7dDzxdh6BAPWgTSBzY0GqN9QgeHg040giaEOSElCUEGBICrOLh8LIJnGEYRiHz94UnIjzdKQRONZOWu9V29DYMwyhkLhnyDPCMGSJNFM8EzjAMo9Dx5A9mhDRx1ATOMAyj4Jkw+CXgWTNEWrgmcIZhGMURxf3JjJCOvZxVJnCGYRjFwKVDnkd50QyRIuK+ZgJnGIZRLDjcakZIiY/oVfe8CZxhGEaxsFYeAVaYIZLigfycieNbTOAMwzCKhaoDmhG52wyxTVyQnxEJPpYIeA3DMIziIe7dCcTNEFsiC/A4jkhw4uZPzCiGYRhFxg3vzkK94ZbJBBDm4On1REOPgXztACXmKYZhGEWGEgWGd95gjYUoNbhSTU3w/cSH4W8UM4EzDMMoNkrKphJvuAMo70RX/TEwA0fuZ3LwjdR00DAMwyg+rntnKuiPOvgQ5VJgKiI1VFe8uOUQpG8/wLzEMAyjCBGNovyoA17ZZ8AjbRU1EzjDMIxip6zkURrjTUBZB7iaFYg8jLpRBr3/IlVVXkb6AOYlhmEYRcp1b89GGVakQ5S1ePooHjX0XPMEE8e3ZNo8FsEZhmEUL08Dw4qovutRZqBODY3NT1ITbM7myUzgDMMwihVxnka9vxZ2HWlAeRahhtKSh5k4sj5XpzaBMwzDKFbqDnyTHu+sBvoXWM0agWdAaujSMIXbghvzo62GYRhG8XLt2zFUKwrgHZyL6hxUHqAL07h5RF2+TWMRnGEYRlGj/wQq8liBp1GpBncad5xaW0iWMYEzDMMoZjx9E8njYFxD02juPW1DIZrGdhMwDMMoZurdeYCbt/N3Ly3YdGEmcIZhGMVM1RH1IP/O2/ndgAmcYRiGkS30jbydukRM4AzDMIysMS9vZ/ZaTOAMwzCMLCEsyN/JSws2F2bxzaI865GdaGnZA9gZcfojXhkq3RDdAFKHSh24yylvfJdJ5zUW7HWMeagvlO5BXPsjWg50RaQP0DXxf21CnXrUq8VxlhHnI2qCXxTWRahQ+cj+4B6MMhDoCwRIvPCuA1mKw/v0qJ2XjTxzSbngzlLW9z4UGIzIwFa7JuqmshJHlxGXd6mpeK892cozytA5Jey8ZiCetx+wC+J1Q6UM0Q14NOA4n6DuEiKVHxesXw+fVUaPjXtTwva4Wo5oL8TpDloO9EbFQ1iPeo2oLEVlKfARNUEXoz2xyid5m2fiuQW7njq1io15ZA+8eDh5W6dPEA2/ndHajbu/Oy3lQxHvOJDvohzU2oimQhzlPYQ3UX2MLs2zeODsTTm38AV3lrKh73dBj0F1P5D9gX1pW+aBFcDrqDxBIDCTyaM/yY84x76Fp+OBHwHbp/CNTQgv48lcAoEHs1dvFULRUYicA/wQ6JbCl1aB/BP06dbdgdfn1JZnT+lHS/MYPDkZ4VigR0p1Vl5EZDqB5ik8dFZ+FtRWxPYnoMNQDkLYt9Wvd2/DyNAmkLdB54I3g0j41YLpdBQLVa93o1tgU14Weot+l5tPfrV4BS5cfQI4z/g15URCd2XgoelKiY4ACaF6SoqNVCqsR7kPT67OeiRUERtIQH8EnAAcl2KjlXZrDvI0jt7E5NCsnAmbq39AOJW2Z8HxUJ4AvYVo+PHMRZKx0/D4A8Kh7TjQJtAIAecmHgrOz64tH94XL34FSJD2bXfSAHoP6DVEKpdmtc6jpveka8MohBNBTgB2y9KZ/o3KbXhMpCbYYOqVItfMW4Vq/9xnMuFIbv3hv0zgkjH2kV2Jxy/D4ccoPbN4zRsRqtj/vRsytefQ5uGlAatGojoe4Qfk9P2mzMXlp9QE389aZBSOXQ78NcPXNZuAXNouMamI9aCEe1HNZCYHD/QhSrv8Nw+csTKjphw5sxs9Nv0VlYvI7CuCBuBKXLkh48N94erDUGc8DmOy/Gxuyaeo/oJoeIqpVyoC99brqPetnAuc636P20e8UogmKYxJJuHYj3HjHyJcmoMHqAfKtSwa8jhjH+yVsaMOWPke6BSEH+berjqUgL5BZfSsLESjPQjFpgNXZeG6jsfjinbUbR8C+mqGxa31uZBxtLSEM3rUUORAutfPQ2UCmX//3RX4PwL6VOL9bqbqHL0WnDcRxudY3AB2R+QRwtGJXHBnqSmYXz/Xy88rC0cK9h1cgcyidN8DuuRYFE7CLZ2TQZHbIc9G7I5yP5WRSzN2xKoqh4A+hDAye7deb2rT986e0o+APg4MztLYxgZc+UfGjheMnojIC8B+WfaD4/ECL1E5ecfM2EF3KIAG4nzq+k5n+KyOsHN19vCcZXk5rzoFK3CFMYsyUvkSoeh8hIOSlGoEeQ3xXgE+RJ1leNpEQFqArnheH0T2QjgI5fgUBedw3C41VFUNz+hwpT8NwAvAm4guBucThLUIzWhgE9rUA0r643k7gBwBnORjmy+bZZXrCcc+JxKMtruWiwbfAIxK0csXgDwFfAyyGgigbA86OPHOhj238qU3iYVeTLte595XTmN8BrBPCqXjwCvAHES/AFmNp90R2Qk4BDgR2G4r13MvNaHMTDgJRo/FYUZrlJWMNcB0hOdB/o04q9HmLlDSH2UAqscijNiGLb/qBoPwAk9QERua40kzCryD8mIis4b3IaKrcAJxCNTitpThOP1A+wP7oXIS6PdJ6R2kDqf3hruBcaZk2+yMbCQvU3O8lkI1SQEtE5CJoDdv4dRLEKpRnYUbeD3l3V8rYgFKOB7lCtBjfCO5RYMnADdk+QLjII8heg9xeSaNl+eR1msaQoC/gp7mK3LoRMLV/2rXdPJw9THAJSlI6jN4+lui4deSlqucfAAaGAf8DEhEzdrG6K2p2y9Aj/J76lDuoqTkzzw0ellSXxE9GkfHt074KAE8PG7OyF2vfHgQ6vqJ22qgClfu9fGL6FcE82rgyCT35VBKuAsI5kDW3kK4G3EfpnrMijS+eQ0Vsd4E9HLgUvwnlJ1FZfQZqkP/wNgam/Jz2kDBClzhTDJJOPpyIIAwGeQuqitead90YRXCsZ8At/mI+UZc2Yua4Kq2C0J0/eaGe+uNwCyioVPafcfCsRDo/fgP6T5MJFTRdrvVvAz6XZ+CfyYSvDKte3Tu1D40NV2BSoj1Pffm8RFN6QnG5P5oYDHQO0mpeoSxVIempXXsUGRvRG4CXCKh09p9rypiXXH0X0mjb2EOuJVpCkNCmAP6J+C3Pk/4ue0ShHDkfpDkUZMrZSl3Prd9PfsQ0KeAgT4lVxNo2TtvSyMKmWvmTUD1xtwvE3AP4OYRCwvRJIWTyaQmuB7kLEpKBlId+i+qgy+3fy2MKJHQXaiOA5INQfagxPtlUThxJBgFqWgdDkrGaMbGDmrTOULRk/3FTW8nEroi7Xs06fR1VIcvw5WD0xa3hMte6iNugJyftrgBRMMfEgmdiivnZaZjq39JPrQsj7Ku5/C0xS3xvLhEQr8DrvSJrq5i1PSeBe/XNcHF4H0f+MynZH+80otMzQoogpOSgo3gCitVVyQ4lQdHf57x40bDkdaoJ1nQch5D5xRHZpdIcAZwt2907upP2hjXj/YpsZzyhvZ1CGqCa9sWXPrWbQaR4OS81O3r0eBg4OIkRn6HTV1DbRP5r/pC6H9BHk1SYgDdGouk81a5HNWfpuAD55uWbdUw+RE4jRfsWsVOlItSfwcka0x2ZIeVxxTN5Yh7BeDTc9KT0j5uVZUDcqpPqb/nJQ1aRWx/kEFJy3hcUxj3R64CtjW1vRmJj2HmyPqMnMvlIiDZ/biQc+8rLwq/joYfBXnJp9RAxjy8rwnaN3yuPi/ndbuuM4ErhN4hPO9jjeOK5nqqx6wAedLH4/enIjYgreMuGLIXsKOPuD6al2su0SN9SqxhyHsv5/3eVMSGQNKlFX+nekzmkuPWBD9FSfaebQcau1cUz8Oqk3yLeO5QU7QtzSb5SEYZ57ahmwrVJJ1tN4HkqaGUI4vqakTn+pUgwHfSPObOPiVaqK7M1wtln7rJ/Bwv99jGU6W/YNsTuOopLf2/zJ9THkzu2xouGr92AnP9C/lOgOqEAuflI0qvK+S8oZ1L4ETe9ZGDfYrqelxSSG6t6S34DeAX8a3Nm0NrKnXLM+feV46QJFrSWMbTfwFUV7wIfJzEt0/IaOaebDJ59GJgo0/TtSPGlp2cLnk467qCNknn6uG4q31K7F5kEZz/sgZJc9cCT/1SIuWxkfStW4+835PG7sNJNsvTk/uz5QygyUYoyoiXHFssjg26xscX+pmibWmSPOysrXxRyCbpbEOUfgJXWjQv4wECpRtS8MD0BEkcv2N2pSK2fZ4eYJ+66Z4F0DYne/dWR591L2Tx5O/4jGAcVTyPqs+9Fr+lIp0RLx+pzJabwBVOx9B/MarXu3vRXE+Lm4WhQtd/y5USHZGnG+hXt/2oiOV3mFkZlqT+c7K78avnI3DF9I5ZPIw0TSYmcJ08gkulgQp06utf33shfssPVC5OLCfI9QPs+r9zDOjP82a7cPWeJMsTqbyW3YjefdfHtwfZA96RA7g8CJzweSGbxATO+DqPj2hC8BlG0yN4f1Dus0m4gdcBvxRNP2NM7Dt5sZ04h/qI77ysnj+RvirZWs+dimaiidGWoDcPEZwsK2STlHS4mzx0Tgm7rBqMy/6t72QSP8JA1C8Lu9EqYJNBhvlEcdcTji0jEpyas2rVBBsIR6aAnJukVCmezqDy4aFUn7kox9H/gUn/3iIf5qAWG0iWnT9eMhBSmX1rFN9jm4f3kiKLTeCyKWY7rjgMh8NRDgc5DFYehEv5Vm6+kbJXNFfTUlYF7JLcd/RhQrEr8bgq47tIb/shvhFhHCQdSt4Rz32ZcOyc1rRmuWJI0ppv7PFxjgSuf5KOyfbm4B0Ux9keL9evLls+LGiTFN1NDFfvTGXkQkLRGQxYuQaRV1G5A+QC4NtAuXl6O3ng7E2o/iol/xH9MwF9lcpYbrLARMNvA/67Vgh9QKdTGYvlLK2TJO0QNLU776QfFbHeCMknUon2NwfvsBFcrjsvddw8YlUhm6Q4IriRM7vRvSEI/Bfo0SgOYv6cXSEJTaYydhLK2SmUPhzVuYRj81DvRlbsOJm5w+JZq1t9+eV0a/weiQ1LfR56rUDd0YRjs/D0JmKhZ7LYwCTLtJKZhLRD55Sw85qBqDsIZX8SO4TvBwwC3dF3pEKkjzl3h1W4XHdeFhe6RQpb4Cpi2xHQX6D1FwNtfTBXJHYX1g8S/+c39iCkFI4o8dj5BHQPSDVHpx6GyD8YsPKPhGI343FPVnaUnnHaBsLVI8F5Bd/0Xf8ZqdBTcTiVcPQVkBv5YvtHMi7CQjKBSU/gxk3ZgZam/RFJiJg6+yE6CF25Fx6l7bitpebbHVbgcp3d5V0TuLb2UndaOQHVK4DeaURrHyK8hiev4fAqm8reZsZpXy4YrZy8IxowgUuVmmAzI2eOoEf9PSjp5DLcE9HrKKGKUHQS4l3frt3Ft0akcikVse8RYBroYWl880jQCANWLiUcvZX68tu+5iPti+CSraGs30oHrgulgV3R+AEoQ0D3QmQvlANpaRmQ0OUvD56R98ieYwLXcTul/XM62UCYbwKXftQ2hMDKyWgKw0/ggvwTZRqBwDQmj/7EnDzDzBxZDzqGcOwt4I8km6H3zQa/J8LPwTmfysg1bOx+dca2iEkI8KeMnPl9um+6w3fX6W+yG3AV3RonEI79ikjFg+3KsVkR6wKa7J12GeHoRSitUZnuB7o7Xtz5aouRpfbpc4QPUP0AR141p+6A3LqgB5uau+Y2YPTJnGMCtwXh2OmI/gPFbwfiz1C5pXUIbJV5d9a7akqEqxnz8BRc90aEdDOZlKNyJd03nUNl7L+oDs7OrABzNsHofTh6M8gBaR5hJ9D7CcfG48bGURP8qE31aCoro1ujn6DekhiNyIqKrQQ+SAzFS0LMRBfjBj6gJrjRfLiDUx/P/ezYgGcRXBriFgJ9yCeTSCMqf8bjemqCDebVOWbymR8Ap1AZOxnlv0GPh3Sm+8geqD5JZeR/qA7fmNG6xUJzGDrnUAasPA/h0sSQX1ocTUBfI1wdIlL5bNrn773eoyXr62xrgSWILEF1CcgShIXEmZ+Vd51G8eDpnjmeePc5N578eaGbpTAELlx9AugDJFvbJCwkLhXUBBeaN+eZ6uATwBOEIgcicgkwFuiWss+p3EA4OpBIaEJG65WYNHIX6N1U1pyI6gRgOKkvh+kHzhOEIuOIhiNpnbuxvJFABiIzZR3Ch18TMU+X0KVkAQ+O/tycz9h6NMW+5HIJnPByMZgl/wI3bsoOtLQ8AMlmhsnrxPkhNcG15skFRDT8LnAB5069nKamcahcAinvqXcJ4ehyIqGrs/D0KdU8DTydyA/pXAD8FOib0jMhMolgdAWx0JyUT1kTdAlHW5L78WaaQD8DZyHogs0iVlKyhMlnfFTIG0gaBcveOT2b8i8TuFRoab4aZKckJZbhMtLErYCZdPo64GaGzrmdAavOAv0b+G5OCvA3KmOvZfSd3JYkZm/+lorY1QT0F8Cv8E8GUIbDw4ybMjjNzUnrElHgNnu9Y4jLHGqCX5jTGBkWnNzuoiH6SjGYJb+ZTCpiQ3xnv6lebA1CkTB3WJxIcBJOfAjKIykNdKjekpiBmGVqguuJhKqQwGG++6Yl2C7R+UqrkUm+dYjLKvNlI0sKl0uBa6GUN0zg/AjohSTPKfga0fB0c94iY/LYWga/FwS9PYXSgynxzs5Z3arPXITLscCLKejvOVTE9k/j6Mt9nrZ9zDmMzGubCkguhyhf5dofbjKBSx69BYAzffr3fzfvLVKqqjxc5+cgc/0fUOe8nNatJrgeV84E/KIpocQ7N+XjCp/6lNjbHMPIONfM2wnI3UbNorOLxTT5E7iAexiQLLWMS2np4+a9RUxN0EXiE/Bd+KVHURHbJcd1+wKVP/mLr1SkcVSf1EViG44aWWjFAzn2K51bNKbJ46n90iv9m/vPWGPeW+RUj3kH5Dl/d/COyHndum66D/BbBL0XFbHtUuvZis8+a3osF9xpqbKMTPOt3Gkbjazr8pIJnD+DfQz5vvltR0H9F06LHJTzak06rxH1fRcnlJBa3eK8BSTbF68Xdb2ONH8wMorkUODQ2Uwa1mgC528ovzVJq81zO8wD+J5/mTztUyb4Jw7wvH4pHSuRTeQ1n0fuJHMII8Ntae4EzpHHisky+Ryi7OVTwFJxdZjnz0thqFl65al2/usrxUmnbk/6/H00qO1maGSGv7/SK6czKDUwywQuJUOp+vSse5n3dhA8xz9Jo9KUp9qlsgavOY0e7jSfEoOprBlmTmFkhKaywyFnWSjf4cZhH5vApYKo3x5c/c17OwhO0kw1/yFPu0Ko/4apnqaezWRy8C2Ut3zEvMqcwsjQs3V4DhvtaUVnnvydWpb6RHADzXs7CKLHphDR5yuJtn/dHC+9ujl6r8/FHkMocpo5htH+/pl8O3dq4UVN4FK+MT4NmjKEcPVu5sFFTkWsK8pIP29A9Pmc1y1cfRjIvj5V+4BI5fK0jrux+z3AiuSiL7dREdveHMRoRxsqCENzdLb5XHdi0e3kkj+BKyl9wf8GBqyXW+yU6KX4DjfLq2mLSEYaCOfPKYSf6aeKmzmyHpVrfErtTEBrGD6rzJzEaBM3vD2E1JKaZ4JoMZoofwL30OhlIK8nb1v0N4y7v7t5cs5b/sy8tA5FDkf5XQol78p53cKxH6ewM7mHBO5p0/HretyawhKE4+i9cSojZ3YznzPSRgLH56pBIECkGE2U32TLqF/jsTPxLn8xT84x4egdhKO/Zeictm+nNDZ2ECIz8M+R9xEuD6R0zKoqh3Dsn4QiZ7RT3M5MKRG0EKP6zEVtOsfjI5pQ73zw24ZSh9O94eXEzhoZZNT0nlRGLycc/ak5dEfth+oJuRFSnuf/TvjQBC5d1ve8D1jq02GfQCh2pXlzjjh7Sr/WLYz+woCVCwhHL2LU9J4pf78i1oVw9CJcfQXYJYWHZwI1wdSm4S8c/APgaEQeIRydSyhyRmvS7tSvLRy9CTSG38akwgbUu7xdtoxUvgRckUJLdTABnUdl5DrC1Tu3+XxVVQ7h6mMIR2+iW+PHKFeD/g9VVY45dgcjFgsgKUyQyoiQyn3Faqb8bnj6+IgmQpELEZmZvLHRPxKKHoEnF1MT/LQdN8omrfjR0nIu0LX1t/2AW+jWeBXh6HMIz+PyIo73KW5gNTXBhs3RQnnjwQT0JNQ7B2SPFM92F9Whmal3x+RnX8nbfBwixxHQLwhH5yD6HOL8Cyewgm6rVzNxfEur4G5PgO+ADqel5WygZ4q+chGRyqXttmck+DfCsQOBSp+SXVD5JcjFhKNPg8xAvZeo776EmSPrt9KRCFAW2IGWloMQOQzhUBYxlG+8k5G9eH/ICcDT5twdiOVDDke9vjk400YaUtrb0QRuq0TDjxKOXgv8t0+PeiQBPZFwdBoOD9Iiz1MT3Oh7/HD1nuAcD3Im6A/tyfCJABaxtSGtHsApKKckYn4HAgrh6CYgAI3lraKQzrjHXNb3+HnKxcPVu4GeupW/DAAqUalEFbw41PWBcHQ90B30Sx/XVDtCXEM0+EBmjCpKrzvPoa63AxJK4QtdgFNAT0EEute32llXg2wA+iD0RrUn8TiIpHJt55vAdTA8/UFuTqTV3Hb8xmI1U0lB1GLQe79i0aC+ID/2KdkVqMSjkoB6hCMfgrMQvDqQOkSbUHqA9AF2B/Zh8ww+tYfCj4WDf5DmppxtnQA0G5fTeHxEGtlLnAtIvjnulvRu2/PMdUSDv4ZQ5uw6cXwLFbGxOLoS4edtOEJ3kO5pC/Xm8noa46bswANnrDQn7yAIZ+SmSfNuKWYzZVDgxGtH5OCBnk+oZjGif8Lv/Uhri5dYw6T7bs5U0/4JdhtxG1o67UPj+M4qbHd3EPRWeq3/5eYhxNT965Qsd1LqEZ1AJHx3RsXtP9QEXeASQpGXQG5H6JPDO9uFeHMIuNmUoQNw3fzdgBxkMJHnuPbEd4q7SUupWZJU8vW1MzmyKNHgVageCbyQYzusBP6KuAOZPLa20z44X+xwGSqXkZ2dHP6Nx3Ai4Z+nL26A03ICcCvp5IVM3feexZXDqQ7fnXUbR8MRupTu3zqD2Mv+TdVFqJ7D5zvejtExCMiZ5CT/pFv0HaJUI7geKehTfYYagDeBY6iM/QDlktb3ZtnYJHIZ8DjCLOIyK+WZfB2ZucPiwPWMmn4X3ZpGA2eBDqN9s23fBbmRXrX3t0nY/kOi43ExFbG/UaJj8TgLoT17yCnI06h3HdHQUzm1c2Ko8CeEIn8D+SXCWZDR5OKrgRkgUxj03uOJERKj46A/ysFJPqV7G5IcdFiBc1mf0ZpVB58GnubsKf1oaTkV1aGIfA9lH9J7FwNQCywCXQiygIA8w0PB+ZkNAvQPqCTJSqFLsnD/1gK/9gl9Xkn7qDNO2wBMAiZREdsFxzsBh8NR+RZwaFJ/EDag8gboc+BNJ1I5L6NXXBP8DLgGuIZQ5EAcjkVb6yYc4NMZWgH8C5XZeExt14zczHTmPgQu4tz7LqOp2w9QPRXkKGBIGp0KF2ExyDuovoPIP4nzQuuQaAbaUmIIC3zrkPlG/CZg26nMVDrnfpE3zt8RnKOzHvyrXE/V0Hixmyu1MDccvQS4KblBdJ/WBza7DJ9VRp91+6CyPQR6Ab1Be7U2uhtBNgEb8XQdjreB0rKP7OV6hhn7YC+au/TB8friOH1wVXG8DYgup3rMijz2bIUxk/tAeV9w++K5fYAGAoEN0PwJD51VVxT2rYj1oCS+F1qyJzAAtJzNSzekFvUagVU43mfESz7YvFzD6Pj8fcF4PL0DVb78geS/p11mDeXenlQN21js5ko1gvPLd6Z0bfgsJzVOzLxbYJ6eRxJCUQd8WlgVE2Uyta0Re/GSWP7yTuuPYXy1qQ1n/xT6944gbqQ8DKIM9imwmEnnNZrzGYZhZCt6m783ynFZPksdzV1u6Sgmc1IslVzgRN4w7zMMw8gi4pxHtmdPit7ADUet7TwCN3JmN5S9fCK4f5n3GYZhZIkqdVDOzvJZauni3diRzOYvcN0bTsR3mn7JE+aBhmEYWaL/eycD2c2lq3oVVcPWdS6BwzvFxypL2ryliGEYhpECcl6WT/AZZd1u6WhWSy5wFbEuIKN8DH+/OZ9hGEaWuHH+jqiOyrKA/o6qI+o7mumSC1yAcSRfIuDilEwyDzQMw8gSgdKLSOwykS3mUXr0Ax3RdE6S6C0A6rPho0aZPPoT80DDMIwscP3Sroj+LKvnULmUKumQ6dycJH/5HYkNL7cdvYn3V/NAwzCMLFG28Ww2b/mVFSL85ejnO6r5ti5wwejRiF7h8907qB5jGUUMwzCyElmpgEzI4hnqCOhlHdmE30zVFYp8G2EGydN4Lae8y+/NAw3DMLLE7e+PBL8sUu0S0N9Q9f3lHdmEX4/gKqMjEXka2C7Jd1zwxjLp9HXmgYZhGFlCshpdvUrgqDs6ugkTUVq4emeQq1DG+au+XE60cq55n2EYRpa44/0T8PTYLB29CfF+3FEnlnxd4Cqj96KMJbVpqFcTDV5v3mcYhpFFVP83i6FhFVVHv9sZzFiCkuoK+auJhH5tnmcYhpHN6O2Dkaj3vcQGbRnnTXYqua6zmNI/VZewASRs4mYYhpH1yE1A/5Slo29CvbGMP6LFBC7BY6h3MJFg1DzPMAwjy9y1uAI4NEvqeQlVR3WqvMHbWgrwAh5/JhZ60jzOMAwjB9z5einKH7MkbtVceeS9nc2k/xE4BZmPeE/iOA/wUHC+eZthGEYu6X0xMCgL4rYYV3/aGS1agsf36dZlga1rMwzDyBO3L94B0SuzMK+kAc8JUvXtus4pcLHQi+ZdhmEY+WyJ9SqUPpkP3vQ8rvzOvM5qVsc8yzAMI4/ctfhbIOdk4cjX8vvvdOoJgiZwhmEY+aJKHURuzUJb/DjNG37T6QNj8zDDMIw8sdvHF6B8N8NHfYum8iBV34p3dvMGzMMMwzDywN1L9kCYCpRl8KjLicdP4MrDVpuBbYjSMAwj96gKjtwF9MzgUWtR72R+/52lZmATOMMwjPzwj4/PB36QwSPW48kofn2ErWH+CjZEaRiGkVNxW7oL6k0FyjN0xGZUTudXh84241oEZxiGkR9UBc+7BzK25q0ZoYLLD3nCjGsCZxiGkcfo7ZPLEP1hxsQNKrjskBlm2K0jZgLDMIwccP+nR6D6IqpdUE1s96a6xQ8+v2/+rAHlR/zyoKfMsBbBGYZh5I/Yh72BKNAlA0dbh+jJJm7+2EJvwzCMbNNYehuwVwaO9DkqI/jFwW+ZUU3gDMMw8ssDy8aDNyYDOwUsIuCczIQhn5hRU8OWCRiGYWSL6s+OwtNIBoKJpyhxh3PRgV+YUVPH3sEZhmFkRdw+3RlPa5B2p+KayJoVp3DhwbVm1PSwIUrDMIxMM3N5N+p0JujO7ThKA6I/46LB/zCDWgRnGIaRf1SFDXoPwuHtOMr7wJFcaOJmAmcYhlEoRL74PUK4HUd4CC9+BBcOeseM2T5sobdhGEamiC4/C+V+VMV/0faWv+s6VH7F+H0mmiEzg82iNAzDyASxz08BibSpXRUeJ+4N56f7zTVDZg6bZGIYhtFeHvniSFxioOm2qV8Al/GTfSabEU3gDMMwCixyW7kPnk4H7ZbGtzxUHqKk9Becs+saM6IJnGEYRmEx9fM9cfVZlB1S/o4wG0/+hx/v+aYZ0ATOMAyjACO3tbvjxZ8F3T3Fb7yH8AfO3rPGjGcCZxiGUZg8UrsHxOcAA1MovQDkb5TvGiEorhnPBM4wDKMwmbl2d+LebJSBSRMoK2+C/oXFu06jSjwznAmcYRhGYYub681m21vfNINMQbmVsTu/YAYzgTMMwyh8Hl09GFefBHb7xt9E3sPTB5HAvYR2sIz/JnCGYRjFErmt/g6e8xho/698ugzhEdR5kDO3f92MVHhYqi7DMIxkTFt9Io4zFegK+gYuj+K4jzJq+7cQUTOQRXCGYRjFx9R1e+O4xyCEaOBFgv3Wm1GKh/8HX6iES4MGrocAAAAldEVYdGRhdGU6Y3JlYXRlADIwMjItMDItMDFUMDM6NTg6MDIrMDA6MDCwxalDAAAAJXRFWHRkYXRlOm1vZGlmeQAyMDIyLTAyLTAxVDAzOjU4OjAyKzAwOjAwwZgR/wAAAABJRU5ErkJggg==" alt="Janssen Logo" width="150" class="jj"> </div></div><h1>Clinical Trials Weekly Digest</h1><br>

<h4><a href="#clinical">Clinical Results Press Releases</a></h4>
<h4><a href="#new_lc">Lung Cancer</a></h4>
<h4><a href="#new_it">Intratumoral</a></h4>
<h4><a href="#new_ct">Cytotoxic</a></h4>
<h4><a href="#new_ia">Immune Activation</a></h4>
<h4><a href="#approvals">Drug Approvals / Applications</a></h4>

<form action="https://getform.io/f/387eb37d-4992-430e-99b3-0bd1f47d1fb2"method="POST" id="interest_form" enctype="multipart/form-data" name="interest_form"><div class="form-group"><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ###### CLINICAL RESULTS ####### -->
<!-- ############################### -->
<!-- ############################### -->

<h2 id="clinical">Clinical Results Press Releases</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>ITM Helmholtz Munich</td>
    <td>ITM Helmholtz Munich and University Hospital Mnster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05533242" target="_blank">NCT05533242</a></td><td><select class="form-select" id="select_form_1" name="NCT05533242"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>BerGenBio</td>
    <td>BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05469178" target="_blank">NCT05469178</a></td><td><select class="form-select" id="select_form_2" name="NCT05469178"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Molecure</td>
    <td>Molecure announces first patient dosed in Phase I trial with novel first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05759923" target="_blank">NCT05759923</a></td><td><select class="form-select" id="select_form_3" name="NCT05759923"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Bio-Thera Solutions</td>
    <td>Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008 an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05620017" target="_blank">NCT05620017</a></td><td><select class="form-select" id="select_form_4" name="NCT05620017"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>SELLAS</td>
    <td>SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02737787" target="_blank">NCT02737787</a></td><td><select class="form-select" id="select_form_5" name="NCT02737787"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>SonALAsense</td>
    <td>SonALAsense Announces Completion of First Cohort in Phase 2 Study of SONALA-001 Sonodynamic Therapy for Recurrent Glioblastoma</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05370508" target="_blank">NCT05370508</a></td><td><select class="form-select" id="select_form_6" name="NCT05370508"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Sermonix Pharmaceuticals</td>
    <td>Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05696626" target="_blank">ELAINE-3 (NCT05696626)</a></td><td><select class="form-select" id="select_form_7" name="NCT05696626"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>AM-Pharma</td>
    <td>AM-Pharma to Present Data From Phase 3 REVIVAL Study at Upcoming Scientific Conferences</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04411472" target="_blank">REVIVAL (NCT04411472 )</a></td><td><select class="form-select" id="select_form_8" name="NCT04411472"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>SpringWorks Therapeutics</td>
    <td>SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03785964" target="_blank">DeFi (NCT03785964)</a></td><td><select class="form-select" id="select_form_9" name="NCT03785964"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo1" class="accordion-toggle" style = "background-color: #E1EBEE;">    <td>Bio-Thera Solutions</td>
    <td>Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007 an Antibody-Drug Conjugate Targeting Nectin-4 for the Treatment of Advanced Solid Tumors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/" target="_blank"></a></td><td><select class="form-select" id="select_form_10" name=""><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>

<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW LC ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_lc">New Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>EGFR-mutant locally advanced or metastatic non-squamous NSCLC</td>
    <td>Biotheus Inc.</td>
<td><p>Phase 2|Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_1">Study Arms</button></td>
    <td><p>PM8002; Placebo; Carboplatin; Pemetrexed</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_500">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05756972" target="_blank">NCT05756972</a></td><td><select class="form-select" id="select_form_11" name="NCT05756972"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced/metastatic solid tumors</td>
    <td>Coherus Biosciences Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_2">Study Arms</button></td>
    <td>CHS-006 (anti-TIGIT); toripalimab (anti-PD-1)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05757492" target="_blank">NCT05757492</a></td><td><select class="form-select" id="select_form_12" name="NCT05757492"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation</td>
    <td>Taiho Oncology Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_3">Study Arms</button></td>
    <td>TAS3351 oral administration</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05765734" target="_blank">NCT05765734</a></td><td><select class="form-select" id="select_form_13" name="NCT05765734"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Locally advanced non-small cell lung cancer (NSCLC)</td>
    <td>Peking University Cancer Hospital & Institute</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_4">Study Arms</button></td>
    <td>Tislelizumab</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05758116" target="_blank">NCT05758116</a></td><td><select class="form-select" id="select_form_14" name="NCT05758116"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Small cell carcinoma of the urinary system</td>
    <td>Sun Yat-sen University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_5">Study Arms</button></td>
    <td>EP/EC+PD-1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05760053" target="_blank">NCT05760053</a></td><td><select class="form-select" id="select_form_15" name="NCT05760053"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Epitheloid malignant pleural mesothelioma</td>
    <td>University Hospital Antwerp</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_6">Study Arms</button></td>
    <td><p>Dendritic cell vaccination; Atezolizumab; Platinum/pemetrexed based chemotherapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_505">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05765084" target="_blank">NCT05765084</a></td><td><select class="form-select" id="select_form_16" name="NCT05765084"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Extensive-stage Small-cell Lung Cancer</td>
    <td>Sichuan University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_7">Study Arms</button></td>
    <td><p>serplulimab; Cisplatin; Carboplatin; Etoposide; Thoracic radiation therapy (TRT)</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_506">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05765825" target="_blank">NCT05765825</a></td><td><select class="form-select" id="select_form_17" name="NCT05765825"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC)</td>
    <td>Pingping Song</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_8">Study Arms</button></td>
    <td>WX-0593 Tablets</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05765877" target="_blank">NCT05765877</a></td><td><select class="form-select" id="select_form_18" name="NCT05765877"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Locally Advanced Non-small Cell Lung Cancer</td>
    <td>Shanghai Pulmonary Hospital Shanghai China</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_9">Study Arms</button></td>
    <td><p>Serplulimab; Carboplatin; Pemetrexed; Nab-paclitaxel; Surgery; Radiotherapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_508">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05766800" target="_blank">NCT05766800</a></td><td><select class="form-select" id="select_form_19" name="NCT05766800"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo2" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_1" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects will be administered with PM8002 plus pemetrexed and carboplatin via intravenously (IV) Q3W for 4 cycles followed by PM8002 and pemetrexed until progression or for a maximum of 2 years.|Subjects will be administered with placebo plus pemetrexed and carboplatin via intravenously (IV) Q3W for 4 cycles followed by placebo and pemetrexed until progression or for a maximum of 2 years.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Placebo; Drug: Pemetrexed; Drug: Carboplatin; Drug: PM8002</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate (Part 1)|Progression free survival (Part 2)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression free survival (PFS) is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause whichever occurs first (based on RECIST v1.1).; Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR) based on RECIST v1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_2" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Advanced solid tumor participants will receive CHS-006 in combination with toripalimab Q3W|Advanced solid tumor participants will receive CHS-006 in combination with toripalimab Q3W|NSCLC-NS participants will receive CHS-006 in combination with toripalimab Q3W|HCC participants will receive CHS-006 in combination with toripalimab Q3W</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: CHS-006 (anti-TIGIT); Drug: toripalimab (anti-PD-1)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Assessment of safety and tolerability of CHS-006 administered in combination with toripalimab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Assessed by number of participants with treatment-emergent adverse events (TEAEs) assessed by the investigator as per CTCAE v5.0.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Day 1 of study treatment through up to 90 days post last dose of study treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_3" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose escalation will assess the safety and determine the recommended phase 2 dose and regimen of TAS3351 administered orally.|TAS3351 in NSCLC patients with C797S EGFRmt. TAS3351 will be administered at the recommended phase 2 dose determined in Part A.|To assess efficacy of TAS3351 in NSCLC patients with C797S EGFRmt. TAS3351 will be administered at the recommended phase 2 dose.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: TAS3351 oral administration</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose Escalation: To investigate the safety and determine the recommended Phase 2 dose and dosing schedule of TAS3351|Dose Escalation: To investigate the safety and determine the recommended Phase 2 dose and dosing schedule of TAS3351|Dose Expansion: To explore the efficacy of TAS3351|Phase 2: To assess the efficacy of TAS3351</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Objective Response Rate (ORR); Adverse Events; Incidence of dose limiting toxicities (DLTs)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>estimated 9 months; estimated 3 years; baseline through cycle 1(each cycle is 21 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_4" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients completed radiotherapy alone or sequential chemoradiation with 42 days received consolidation Tislelizumab 200mg every 3 weeks for 12 months.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Tislelizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Defined from the date of enrollment to the date of death or any recurrence.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6 months after enrollment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_5" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Toripalimab 240mg D1 of each 21-day cycle IV drip; Etoposide 100mg/m2 D1-3 of each 21-day cycle IV drip; Cisplatin 25mg/m2 D1-3 of each 21-day cycle IV drip; Carboplatin AUC 5 D1 of each 21-day cycle IV drip;</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: EP/EC+PD-1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression-free survival (PFS) is defined as the time from the date of the first dose to the earlier of the dates of the first objective documentation of radiographic progressive disease (PD) or death due to any cause.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Within approximately 36 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_6" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Standard of care chemotherapy complemented with atezolizumab and WT1/DC vaccination</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Platinum/pemetrexed based chemotherapy; Drug: Atezolizumab; Biological: Dendritic cell vaccination</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Proportion of patients that experienced (S)AEs possibly probably or definitely related to pemetrexed and/or cisplatin/carboplatin and/or atezolizumab and/or WT1/DC vaccination|Number and grade of AEs and SAEs|Proportion of patients who completed study treatment schedule</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The relationship of an AE to the investigational agents will be determined by the Investigator as either related or non-related based on their clinical judgment.; Study treatment schedule = administration of four platinum/pemetrexed-based chemotherapy cycles (CT1-4) in combination with four atezolizumab treatments (A1-4) and four WT1/DC vaccinations (V1-4).; AEs are defined and graded according to the latest version of the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>After the chemoimmunotherapy treatment (+/- 18 weeks after entry to trial); through study completion an average of 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_7" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive the following treatment regimens: LDRT concurrent cisplatin/carboplatin + etoposide + serplulimab. Induction treatment will be administered on a 21-day cycle for four cycles. Concurrent radiation therapy will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase participants will continue maintenance therapy with serplulimab and thoracic radiation therapy (30Gay/10f. Participants will be treated until loss of clinical benefit or unaccepted toxicity or withdrawal of consent or death (whichever occurs first).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Cisplatin; Drug: Etoposide; Drug: Carboplatin; Drug: serplulimab; Radiation: Thoracic radiation therapy (TRT)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The time from the date of first dosing of durvalumab to the first appearance of objective disease progression (according to RECIST1.1) or death from any cause (if it occurs before disease progression).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline up to approximately 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_8" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The treatment will be administrated as neoadjuvant 8 weeks before surgery. After surgical intervention the treatment will be administered up to 2 years. Treatment will be discontinued in case of unacceptable toxicity or disease progression.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: WX-0593 Tablets</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Major Pathologic Response (MPR) Rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Major pathologic response (MPR) rate is defined as percentage of residual viable tumor cells histologically detected in the resected primary tumor after surgery 10%.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At time of surgery</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_9" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Other; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>In this arm patients with tumors resectable after chemoimmunotherapy will receive surgical treatment in department of thoracic surgery.|In this arm patients with tumors resectable after chemoimmunotherapy will receive radiotherapy in department of medical oncology.|In this arm patients with tumors still unresectable after chemoimmunotherapy will receive therapy in department of medical oncology.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Surgery; Drug: Serplulimab; Drug: Pemetrexed; Drug: Carboplatin; Radiation: Radiotherapy; Drug: Nab-paclitaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Event-free survival (EFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Event-free survival (EFS) is defined as the length of time (months) from randomization to any of the following events: any progression of disease precluding surgery progression or recurrence disease based on response evaluation criteria in solid tumors (RECIST) 1.1 after surgery or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study. In addition to the relative increase of 20% the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 30 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## EXISTING LC ########## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_lc">Existing Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 126 days; Trial completed</strong></td>
    <td>Advanced and unresectable NSCLC</td>
    <td>Medical University of South Carolina</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_10">Study Arms</button></td>
    <td><p>ALT-803; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_509">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02523469" target="_blank">NCT02523469</a></td><td><select class="form-select" id="select_form_20" name="NCT02523469"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 366 days; Enrollment increased by: 125; Primary Completion Date moved earlier by 487 days</strong></td>
    <td>Front-line PD-L1-high locally advanced or metastatic NSCLC</td>
    <td>Arcus Biosciences Inc.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_11">Study Arms</button></td>
    <td><p>Zimberelimab; Domvanalimab; Carboplatin; Pemetrexed; Paclitaxel; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_509">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04736173" target="_blank">NCT04736173</a></td><td><select class="form-select" id="select_form_21" name="NCT04736173"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment decreased by: 29; Changed status from recruiting to active</strong></td>
    <td>MET-altered Non-small cell lung cancer</td>
    <td>Regeneron Pharmaceuticals</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_12">Study Arms</button></td>
    <td>REGN5093</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04077099" target="_blank">NCT04077099</a></td><td><select class="form-select" id="select_form_22" name="NCT04077099"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment increased by: 35</strong></td>
    <td>First-line and second-line advanced or metastatic solid tumors including non-small cell lung cancer</td>
    <td>Nektar Therapeutics</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_13">Study Arms</button></td>
    <td><p>NKTR-214; Pembrolizumab; NKTR-214; NKTR-214; Cisplatin; Carboplatin; Nab paclitaxel; Paclitaxel; Pemetrexed; Atezolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_510">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03138889" target="_blank">NCT03138889</a></td><td><select class="form-select" id="select_form_23" name="NCT03138889"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Unresectable stage III/IV cutaneous melanoma or with stage IV NSCLC</td>
    <td>Nouscom SRL</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_14">Study Arms</button></td>
    <td>GAd-PEV; MVA-PEV</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04990479" target="_blank">NCT04990479</a></td><td><select class="form-select" id="select_form_24" name="NCT04990479"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment increased by: 133</strong></td>
    <td>Solid Tumors</td>
    <td>Inhibrx Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_15">Study Arms</button></td>
    <td><p>INBRX-106 - Hexavalent OX40 agonist antibody; Pembrolizumab 200 mg; Pembrolizumab 400 mg</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_511">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04198766" target="_blank">NCT04198766</a></td><td><select class="form-select" id="select_form_25" name="NCT04198766"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment decreased by: 123; Changed status from recruiting to active</strong></td>
    <td>Melanoma; Non-Small- Cell Lung Cancer</td>
    <td>Seagen Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_16">Study Arms</button></td>
    <td><p>SEA-CD40; pembrolizumab; pemetrexed; carboplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_511">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04993677" target="_blank">NCT04993677</a></td><td><select class="form-select" id="select_form_26" name="NCT04993677"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Advanced Solid Tumor; Breast Cancer; Small-cell Lung Cancer; Pancreatic Cancer</td>
    <td>Syros Pharmaceuticals</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_17">Study Arms</button></td>
    <td><p>SY-5609; Fulvestrant; Gemcitabine; Nab-paclitaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_511">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04247126" target="_blank">NCT04247126</a></td><td><select class="form-select" id="select_form_27" name="NCT04247126"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment decreased by: 16</strong></td>
    <td>Advanced solid tumors including RET Fusion-Positive NSCLC or RET-mutated MTC or other RET-altered advanced solid tumor</td>
    <td>Shouyao Holdings (Beijing) Co. LTD</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_18">Study Arms</button></td>
    <td>SY-5007</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05278364" target="_blank">NCT05278364</a></td><td><select class="form-select" id="select_form_28" name="NCT05278364"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Extensive-Stage Small Cell Lung Cancer</td>
    <td>Hutchison Medipharma Limited</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_19">Study Arms</button></td>
    <td>Surufatinib; Anti-PD-1/L1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05509699" target="_blank">NCT05509699</a></td><td><select class="form-select" id="select_form_29" name="NCT05509699"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Resectable Stage II to IIIA non-small cell lung cancer (NSCLC)</td>
    <td>BeiGene</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_20">Study Arms</button></td>
    <td>Tislelizumab; Ociperlimab; LBL-007</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05577702" target="_blank">NCT05577702</a></td><td><select class="form-select" id="select_form_30" name="NCT05577702"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>NSCLC</td>
    <td>Akeso</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_21">Study Arms</button></td>
    <td><p>AK119; AK112; Pemetrexed; Carboplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_514">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05636267" target="_blank">NCT05636267</a></td><td><select class="form-select" id="select_form_31" name="NCT05636267"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Advanced solid tumors</td>
    <td>Kineta Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_22">Study Arms</button></td>
    <td><p>KVA12123 - Dose Escalation; KVA12123 Plus Pembrolizumab - Dose Escalation; KVA12123 - Dose Expansion; KVA12123 Plus Pembrolizumab - Dose Expansion</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_514">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05708950" target="_blank">NCT05708950</a></td><td><select class="form-select" id="select_form_32" name="NCT05708950"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Solid tumors with mutated KRAS/NRAS</td>
    <td>Elicio Therapeutics</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_23">Study Arms</button></td>
    <td>ELI-002 7P</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05726864" target="_blank">NCT05726864</a></td><td><select class="form-select" id="select_form_33" name="NCT05726864"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Advanced/chemorefractory solid tumors</td>
    <td>Northwestern University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_24">Study Arms</button></td>
    <td><p>Biospecimen Collection; Computed Tomography; Devimistat; Fluorouracil; Gemcitabine Hydrochloride; Hydroxychloroquine; Magnetic Resonance Imaging</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_515">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05733000" target="_blank">NCT05733000</a></td><td><select class="form-select" id="select_form_34" name="NCT05733000"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Advanced solid tumor malignancy harboring a KRAS G12D mutation</td>
    <td>Mirati Therapeutics Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_25">Study Arms</button></td>
    <td>MRTX1133</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05737706" target="_blank">NCT05737706</a></td><td><select class="form-select" id="select_form_35" name="NCT05737706"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days; Changed status from active to suspended</strong></td>
    <td>Lung Cancer</td>
    <td>Hopital du Sacre-Coeur de Montreal</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_26">Study Arms</button></td>
    <td>Patients with a living donor; Patients with a UCB donor</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02579005" target="_blank">NCT02579005</a></td><td><select class="form-select" id="select_form_36" name="NCT02579005"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 366 days; Enrollment increased by: 125; Primary Completion Date moved earlier by 487 days</strong></td>
    <td>Front-line PD-L1-high locally advanced or metastatic NSCLC</td>
    <td>Arcus Biosciences Inc.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_27">Study Arms</button></td>
    <td><p>Zimberelimab; Domvanalimab; Carboplatin; Pemetrexed; Paclitaxel; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04736173" target="_blank">NCT04736173</a></td><td><select class="form-select" id="select_form_37" name="NCT04736173"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Metastatic tumors</td>
    <td>Memorial Sloan Kettering Cancer Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_28">Study Arms</button></td>
    <td>Sterotactic Body Radiotherapy/SBRT; Standard of care</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03808662" target="_blank">NCT03808662</a></td><td><select class="form-select" id="select_form_38" name="NCT03808662"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 225 days</strong></td>
    <td>Non-small Cell Lung Cancer Melanoma and Mismatch-Repair Proficient Colorectal Cancer</td>
    <td>Syndax Pharmaceuticals</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_29">Study Arms</button></td>
    <td><p>entinostat; pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_518">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02437136" target="_blank">NCT02437136</a></td><td><select class="form-select" id="select_form_39" name="NCT02437136"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 157 days; Enrollment increased by: 80</strong></td>
    <td>Non-Small Cell Lung Cancer; Advanced Solid Tumors; Gastroesophageal Adenocarcinoma</td>
    <td>AbbVie</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_30">Study Arms</button></td>
    <td>ABBV-400</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05029882" target="_blank">NCT05029882</a></td><td><select class="form-select" id="select_form_40" name="NCT05029882"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 183 days</strong></td>
    <td>Locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) excluding patients with a sensitizing EGFR mutation or ALK translocation</td>
    <td>Genentech Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_31">Study Arms</button></td>
    <td><p>Atezolizumab; Tiragolumab; Placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_519">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03563716" target="_blank">NCT03563716</a></td><td><select class="form-select" id="select_form_41" name="NCT03563716"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 517 days</strong></td>
    <td>Early lung cancer</td>
    <td>Andrei Iagaru</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_32">Study Arms</button></td>
    <td><p>Computed Tomography; Fludeoxyglucose F-18; Fluorine F 18 L-glutamate Derivative BAY94-9392; Positron Emission Tomography</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_519">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03824535" target="_blank">NCT03824535</a></td><td><select class="form-select" id="select_form_42" name="NCT03824535"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 2191 days; Primary Completion Date pushed later by 731 days</strong></td>
    <td>Non-Small Lung Cell Cancer</td>
    <td>Emory University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_33">Study Arms</button></td>
    <td><p>Docetaxel; Pembrolizumab; Ramucirumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_519">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04340882" target="_blank">NCT04340882</a></td><td><select class="form-select" id="select_form_43" name="NCT04340882"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 536 days</strong></td>
    <td>Stage II or III non-small cell lung cancer</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_34">Study Arms</button></td>
    <td><p>Atezolizumab; Hypofractionated Radiation Therapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_519">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04310020" target="_blank">NCT04310020</a></td><td><select class="form-select" id="select_form_44" name="NCT04310020"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 398 days</strong></td>
    <td>Advanced EGFRm NSCLC</td>
    <td>MedImmune LLC</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_35">Study Arms</button></td>
    <td>Oleclumab; Osimertinib; AZD4635</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03381274" target="_blank">NCT03381274</a></td><td><select class="form-select" id="select_form_45" name="NCT03381274"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Start Date pushed later by 365 days</strong></td>
    <td>Upper GI cancers</td>
    <td>University of Chicago</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_36">Study Arms</button></td>
    <td>Standard of Care Chemotherapy; Video-Assisted Thoracic Surgery (VATS); Lobectomy; Consolidative Radiation; Ablation Treatment; Resection or Excision; Peritonectomy; Transarterial Radioembolization</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04931420" target="_blank">NCT04931420</a></td><td><select class="form-select" id="select_form_46" name="NCT04931420"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 365 days</strong></td>
    <td>Metastatic non-small cell lung cancer</td>
    <td>Julia K. Rotow MD</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_37">Study Arms</button></td>
    <td><p>Pembrolizumab; PEMETREXED; CARBOPLATIN; PACLITAXEL; InVision</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_521">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04166487" target="_blank">NCT04166487</a></td><td><select class="form-select" id="select_form_47" name="NCT04166487"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 92 days; Enrollment decreased by: 2236; Primary Completion Date pushed later by 1095 days</strong></td>
    <td>Colorectal or non small cell lung cancer</td>
    <td>Peter MacCallum Cancer Centre Australia</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_38">Study Arms</button></td>
    <td><p>Sevoflurane; Propofol; Lidocaine IV</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_521">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04316013" target="_blank">NCT04316013</a></td><td><select class="form-select" id="select_form_48" name="NCT04316013"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Start Date pushed later by 123 days</strong></td>
    <td>Metastatic Cancer</td>
    <td>Williams Cancer Foundation</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_39">Study Arms</button></td>
    <td>SV-101</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05544240" target="_blank">NCT05544240</a></td><td><select class="form-select" id="select_form_49" name="NCT05544240"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Primary Completion Date pushed later by 92 days</strong></td>
    <td>Advanced solid tumors</td>
    <td>MacroGenics</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_40">Study Arms</button></td>
    <td>vobramitamab duocarmazine; retifanlimab</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03729596" target="_blank">NCT03729596</a></td><td><select class="form-select" id="select_form_50" name="NCT03729596"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active; Primary Completion Date pushed later by 242 days</strong></td>
    <td>Advanced non-squamous NSCLC harboring a HER2 exon 20 mutation</td>
    <td>Jiangsu HengRui Medicine Co. Ltd.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_41">Study Arms</button></td>
    <td><p>Pyrotinib; Docetaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_523">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04447118" target="_blank">NCT04447118</a></td><td><select class="form-select" id="select_form_51" name="NCT04447118"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 699 days; Enrollment decreased by: 22; Trial completed; Primary Completion Date pushed later by 730 days</strong></td>
    <td>Immune-sensitive metastatic cancers</td>
    <td>Kidney Cancer Research Bureau</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_42">Study Arms</button></td>
    <td><p>Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_523">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04749602" target="_blank">NCT04749602</a></td><td><select class="form-select" id="select_form_52" name="NCT04749602"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 304 days; Changed status from recruiting to active; Primary Completion Date pushed later by 226 days</strong></td>
    <td>Advanced solid tumors</td>
    <td>Mundipharma Research Limited</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_43">Study Arms</button></td>
    <td>Tinostamustine (EDO-S101)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03345485" target="_blank">NCT03345485</a></td><td><select class="form-select" id="select_form_53" name="NCT03345485"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 366 days; Changed status from recruiting to active; Primary Completion Date pushed later by 365 days</strong></td>
    <td>Brain cancer or cancer that has spread to the brain</td>
    <td>University of Southern California</td>
<td><p>Early Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_44">Study Arms</button></td>
    <td>Computed Tomography; 18F-FMAU; Multiparametric Magnetic Resonance Imaging; Positron Emission Tomography</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04752267" target="_blank">NCT04752267</a></td><td><select class="form-select" id="select_form_54" name="NCT04752267"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo3" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo3"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 319 days; Enrollment decreased by: 14; Primary Completion Date moved earlier by 347 days</strong></td>
    <td>Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer</td>
    <td>Pfizer</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_45">Study Arms</button></td>
    <td><p>PF-07248144; Fulvestrant; Letrozole; Palbociclib; PF-07220060</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_525">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04606446" target="_blank">NCT04606446</a></td><td><select class="form-select" id="select_form_55" name="NCT04606446"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Extensive-stage small cell Lung Cancer (ES-SCLC)</td>
    <td>Merck Sharp & Dohme LLC</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_46">Study Arms</button></td>
    <td><p>Pembrolizumab; MK-4830; MK-5890; Lenvatinib; Etoposide; Cisplatin; Carboplatin</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_525">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04924101" target="_blank">NCT04924101</a></td><td><select class="form-select" id="select_form_56" name="NCT04924101"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 670 days; Enrollment increased by: 80</strong></td>
    <td>Advanced or metastatic small cell lung breast and ovarian cancers</td>
    <td>Pfizer</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_47">Study Arms</button></td>
    <td><p>PF-07104091 monotherapy dose escalation; PF-07104091 + palbociclib + fulvestrant; PF-07104091 + palbociclib + letrozole; PF-07104091 monotherapy dose expansion (ovarian); PF-07104091 monotherapy dose expansion (SCLC); PF-07104091 + Fulvestrant (post CDK4/6); PF-0704091 + Fulvestrant (post CDK4/6)</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_525">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04553133" target="_blank">NCT04553133</a></td><td><select class="form-select" id="select_form_57" name="NCT04553133"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment increased by: 90</strong></td>
    <td>Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation</td>
    <td>Bayer</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_48">Study Arms</button></td>
    <td>BAY2927088_formulation A; BAY2927088_formulation B_1; BAY2927088_formulation B_2</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05099172" target="_blank">NCT05099172</a></td><td><select class="form-select" id="select_form_58" name="NCT05099172"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 309 days</strong></td>
    <td>Metastatic NSCLC</td>
    <td>AstraZeneca</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_49">Study Arms</button></td>
    <td><p>Durvalumab; AZD9150; AZD6738; Vistusertib; Olaparib; Oleclumab; trastuzumab deruxtecan; cediranib; AZD6738 (ceralasertib); AZD6738 (ceralasertib); AZD6738 (ceralasertib) (240 mg or 160 mg); AZD6738 (ceralasertib) 7 days monotherapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_526">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03334617" target="_blank">NCT03334617</a></td><td><select class="form-select" id="select_form_59" name="NCT03334617"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 230 days; Primary Completion Date pushed later by 118 days</strong></td>
    <td>LS-SCLC</td>
    <td>AstraZeneca</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_50">Study Arms</button></td>
    <td><p>Durvalumab; Tremelimumab; Placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_526">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03703297" target="_blank">NCT03703297</a></td><td><select class="form-select" id="select_form_60" name="NCT03703297"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from recruiting to active</strong></td>
    <td>EGFR wild-type advanced non-small cell lung cancer (NSCLC)</td>
    <td>Novartis Pharmaceuticals</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_51">Study Arms</button></td>
    <td>INC280 (capmatinib)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02414139" target="_blank">NCT02414139</a></td><td><select class="form-select" id="select_form_61" name="NCT02414139"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 179 days</strong></td>
    <td>Previously untreated locally advanced or metastatic non-squamous and squamous NSCLC</td>
    <td>Novartis Pharmaceuticals</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_52">Study Arms</button></td>
    <td><p>canakinumab; canakinumab matching placebo; pembrolizumab; carboplatin; cisplatin; paclitaxel; nab-paclitaxel; pemetrexed</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_527">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03631199" target="_blank">NCT03631199</a></td><td><select class="form-select" id="select_form_62" name="NCT03631199"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 365 days; Primary Completion Date pushed later by 304 days</strong></td>
    <td>PD-L1 expressed chemotherapy-naive EGFR/ALK wild type patients with stage IV non-squamous or squamous NSCLC</td>
    <td>Hoffmann-La Roche</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_53">Study Arms</button></td>
    <td><p>Atezolizumab; Pemetrexed; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_527">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05047250" target="_blank">NCT05047250</a></td><td><select class="form-select" id="select_form_63" name="NCT05047250"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 90 days</strong></td>
    <td>Small Cell Lung Carcinoma</td>
    <td>Amgen</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_54">Study Arms</button></td>
    <td><p>AMG 757; Pembrolizumab; CRS Mitigation Strategies</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_527">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03319940" target="_blank">NCT03319940</a></td><td><select class="form-select" id="select_form_64" name="NCT03319940"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 230 days; Primary Completion Date pushed later by 118 days</strong></td>
    <td>LS-SCLC</td>
    <td>AstraZeneca</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_55">Study Arms</button></td>
    <td><p>Durvalumab; Tremelimumab; Placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_527">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03703297" target="_blank">NCT03703297</a></td><td><select class="form-select" id="select_form_65" name="NCT03703297"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 273 days</strong></td>
    <td>Advanced solid tumors</td>
    <td>Boehringer Ingelheim</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_56">Study Arms</button></td>
    <td>BI 765049; ezabenlimab</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04752215" target="_blank">NCT04752215</a></td><td><select class="form-select" id="select_form_66" name="NCT04752215"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_10" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Up to 21 patients will receive ALT-803 + Nivolumab in the dose escalation phase to determine the maximum tolerated dose.||ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. The starting dose level for ALT-803 is 6 microgram (mcg)/kilogram (kg); the second dose level is 10 mcg/kg; the third dose level is 15 mcg/kg; and the fourth dose level is 20 mcg/kg.||Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1 Week 3 Week 5).The dose level for Nivolumab is 240mg.|Patients who have not received PD-1 blockade (nivolumab pembrolizumab or atezolizumab) will be enrolled to Arm A in the Phase II part of the study.||ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.||Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1 Week 3 Week 5).The dose level for Nivolumab is 240mg.|Patients who have had PD-1 blockade (nivolumab pembrolizumab or atezolizumab) and progressed will be enrolled to Arm B in the Phase II part of the study.||ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.||Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1 Week 3 Week 5).The dose level for Nivolumab is 240mg.|All eligible patients will be enrolled into one of two exploratory dosing arms.||For exploratory Arm 1:||The dose level for ALT-803 is 20 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1 Week 3 Week 5) for up to 4 cycles.||Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1 Week 3 Week 5).The dose level for Nivolumab is 240mg.|All eligible patients will be enrolled into one of two exploratory dosing arms.||For exploratory Arm 1:||The dose level for ALT-803 is 10 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1 Week 3 Week 5) for up to 4 cycles.||Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1 Week 3 Week 5).The dose level for Nivolumab is 240mg.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Nivolumab; Biological: ALT-803</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Presence or absence of a dose limiting toxicity (DLT) of ALT-803 in combination with Nivolumab|Response Rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Response rate will be defined by the test overall response which is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The subject's best response assignment will depend on the achievement of both measurement and confirmation criteria.; The phase II portion of the study looks to define the response rate (using immune-related RECIST) of ALT-803 added to nivolumab in patients with advanced and unresectable non-small cell lung cancer.; A continual reassessment method (CRM) design will be used to identify the maximum tolerated dose (MTD) for Phase Ib patients</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Cycles 1-4: Weeks 1-6 of each cycle; While on study at the end of each 6 week cycle; if off study every 3 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_11" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive carboplatin pemetrexed and paclitaxel by intravenous (IV) infusion.|Participants will receive zimberelimab monotherapy by IV infusion.|Participants will receive zimberelimab in combination with AB154 by IV infusion.|Participants will receive domvanalimab in combination with zimberelimab by IV infusion.|Participants will receive pembrolizumab by IV infusion.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Domvanalimab; Drug: Pemetrexed; Drug: Carboplatin; Drug: Zimberelimab; Drug: Paclitaxel; Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Arm D vs. Arm E</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From randomization until death from any cause (up to approximately 7 years)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_12" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Monotherapy in dose escalation cohorts (phase 1) followed by an expansion phase (phase 2)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: REGN5093</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of patients with Dose Limiting Toxicities|Incidence and severity of treatment-emergent adverse events|Incidence and severity of adverse events of special interest (AESIs)|Incidence and severity of serious adverse events (SAEs)|Incidence and severity of grade 3 laboratory abnormalities|REGN5093 concentrations in serum over time|Objective response rate (ORR) per RECIST 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Phase 2/Dose expansion; Phase 1/Dose escalation</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through study completion an average of 4 years; Up to 21 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_13" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Cohort 1: NKTR-214 will be combined with pembrolizumab|Cohort 2: NKTR-214 will be combined with pembrolizumab|Cohort 3: NKTR-214 will be combined with pembrolizumab|Cohort 4: NKTR-214 will be dosed in combination with pembrolizumab and either cisplatin or carboplatin and pemetrexed per investigator discretion|Cohort 5: NKTR-214 will be dosed in combination with pembrolizumab and carboplatin and either nab-paclitaxel or paclitaxel per investigator discretion|Cohort 0 (Before Protocol Amendment 5.0): NKTR-214 will be combined with pembrolizumab or atezolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Cisplatin; Drug: Atezolizumab; Drug: NKTR-214; Drug: Pemetrexed; Drug: Carboplatin; Drug: Pembrolizumab; Drug: Paclitaxel; Drug: Nab paclitaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Participants Experiencing Dose-Limiting Toxicities in Dose Optimization Cohort 1a|Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] for Dose Optimization Cohort 1a.|Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by RECIST 1.1 of NKTR-214 Plus Pembrolizumab for Dose Expansion Cohorts 2 and 3.|Objective Response Rate (ORR) Per Investigator's Assessment by RECIST 1.1 of NKTR-214 at a Dose of 0.006 mg/kg With Pembrolizumab and Platinum-based Chemotherapy for Dose Expansion Cohorts 4+5.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR is defined as the proportion of enrolled participants who achieved a Best Overall Response (BOR) of CR or PR. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to  10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. ORR is calculated as the sum of CR and PR.; A single DLT (hypotension) was reported in 1 patient in dose optimization Cohort 1a.; The Response Evaluable Population was subjects who received at least 1 dose (or partial dose) of study drug had measurable disease (per RECIST 1.1) at baseline and had at least 1 post-baseline assessment of tumor response.; Objective response is the sum of confirmed complete response and confirmed partial response.; *Efficacy endpoint for Cohort 4 +5 is per Investigator's Assessment due to the early termination of the study and incompleteness of BICR data for these cohorts.; ORR per BICR by RECIST 1.1 for the Response Evaluable Population dose expansion Cohorts 2 and 3.; ORR per Investigator's Assessment* by RECIST 1.1 for the Response Evaluable Population dose expansion Cohorts 4 +5. The Response Evaluable Population was subjects who received at least 1 dose (or partial dose) of study drug had measurable disease (per RECIST 1.1) at baseline and had at least 1 post-baseline assessment of tumor response.; DLTs were assesses in the Dose Optimization Cohort 1 a which had doses of NKTR-214 as 0.008 mg/kg 0.010 mg/kg and 0.012 m/kg I combination with pembrolizumab at 200 mg.; Safety and Tolerability of NKTR-214 (starting at dose of 0.008 mg/kg) in combination with pembrolizumab (Keytruda) as evaluated by incidence of drug-emergent Adverse Events (AEs) Serious Adverse Events (SAEs) AEs leading to drug discontinuation and fatal AEs.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Until disease progression death unacceptable toxicity symptomatic deterioration Investigator's decision to discont. treatment patient withdrew consent or lost to follow-up or study terminated by Sponsor; or until maximum of 2 years.; Until disease progression death unacceptable toxicity symptomatic deterioration Investigator's decision to discontinue treatment patient withdrew consent or lost to follow-up or study terminated by Sponsor; or until maximum of 2 years.; DLTs were assessed at 21 days from Cycle 1; AEs reported starting immediately after first dose of study drug(s) until 100 days after the last dose of all study drugs up to approximately 28 months.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_14" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Cohort 1a: 3 patients (expandable to 9) with unresectable stage III / IV Cutaneous Melanoma.|Cohort 2a:13 patients with unresectable stage III / IV Cutaneous Melanoma.|Cohort 2b: 12 patients with stage IV NSCLC (PDL1 50%).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: GAd-PEV; Biological: MVA-PEV</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety and tolerability: incidence of treatment- emerging adverse events. AEs characterized by type severity (graded by CTCAE v.5.0) Timing seriousness and relationship to study treatments.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Changes in vital signs and clinical evaluations.; Frequency duration and severity of adverse events (AEs) and serious adverse events (SAEs) using CTCAE v5.0 criteria.; Changes in clinical laboratory blood samples.; Dose-limiting toxicity (DLT)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 110 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_15" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.|INBRX-106 will be escalated in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors.|Subjects with melanoma (any type) head and neck squamous cell carcinoma (non-nasopharyngeal) nasopharyngeal carcinoma MSI-high TMB-high or MMR-deficient tumors will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks.|Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks|Subjects with non-small cell lung cancer will be treated with alternating every 6 weeks dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV|Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1 followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles|Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106|Subjects with melanoma (any type) head and neck squamous cell carcinoma renal cell carcinoma urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106|Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks|Subjects with solid tumors that have confirmed MSI-high TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pembrolizumab 400 mg; Drug: Pembrolizumab 200 mg; Drug: INBRX-106 - Hexavalent OX40 agonist antibody</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab|Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab|MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0; Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2-4 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_16" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>SEA-CD40 + pembrolizumab|SEA-CD40 + pembrolizumab + pemetrexed + carboplatin</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: pembrolizumab; Drug: SEA-CD40; Drug: pemetrexed; Drug: carboplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Confirmed Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The proportion of participants who achieve a confirmed complete response (CR) or partial (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the investigator.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Duration of treatment approximately 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_17" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose escalation phase to explore maximum tolerated dose of SY-5609 given as a single agent.|Participants with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy will receive SY-5609 in combination with fulvestrant.|Participants with PDAC will receive SY-5609 in combination with gemcitabine in Safety Lead-in to identify a recommended combination dose for the expansion. The expansion part will assess the safety tolerability and preliminary clinical activity of SY-5609 in combination with gemcitabine at the recommended combination dose.|Participants with PDAC will receive SY-5609 in combination with gemcitabine plus nab-paclitaxel in Safety Lead-in to identify a recommended combination dose for the expansion. The expansion part will assess the safety tolerability and preliminary clinical activity of SY-5609 in combination with gemcitabine plus nab-paclitaxel at the recommended combination dose.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Fulvestrant; Drug: Nab-paclitaxel; Drug: Gemcitabine; Drug: SY-5609</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Groups 1 and 2: Dose-Limiting Toxicity of SY-5609|Groups 1 and 2: Number of Participants With Treatment Emergent Adverse Events|Groups 3 and 4 (Safety Lead-ins): Number of Participants With Dose-Limiting Toxicity|Groups 3 and 4 (Safety Lead-ins): Number of Participants With TEAEs|Groups 3 and 4 (Expansions): Progression Free Survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 1 year; From Baseline up to 30 days after last dose of study drug (up to 1 year); Up to 28 days after first administration</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_18" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose-escalation Phase:||Multiple doses of SY-5007 for oral administration.||Dose Expansion Phase:||RP2D of SY-5007 as determined during Dose Escalation.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: SY-5007</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase I: Determine the dose-limiting toxicities (DLT) during the first 28-day cycle of SY-5007 treatment|Phase I: Number of patients with adverse events and serious adverse events|Phase II: Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Characterization of the safety and tolerability; Maximum Tolerated Dose (MTD) and/or recommended phase 2 dose (RP2D) in Cycle 1; Anti-tumor activity of SY-5007</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Dose-escalation Cycle 1 (each cycle is 28 days); Up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_19" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Surufatinib 250 mg orally once plus anti-PD-1/L1 Q3W or Q4W the same immune checkpoint inhibitor from patients' first-line therapy.|Anti-PD-1/L1 therapy Q3W or Q4W the same immune checkpoint inhibitor from patients' first-line therapy</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Surufatinib; Drug: Anti-PD-1/L1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression-free survival(PFS) assessed by the investigator as per the Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>About 18 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_20" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Tislelizumab on a 3-week cycle for 2 cycles followed by surgical resection (each cycle is 21 days)|Tislelizumab + ociperlimab on a 3-week cycle for 2 cycles followed by surgical resection (each cycle is 21 days)|Tislelizumab + LBL-007 on a 3-week cycle for 2 cycles followed by surgical resection (each cycle is 21 days)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: LBL-007; Drug: Tislelizumab; Drug: Ociperlimab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Major Pathological Response (MPR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>MPR is defined as the proportion of participants with  10% residual viable tumor in the resected primary tumor and all resected lymph nodes as assessed by blinded independent pathology review (BIPR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 12 weeks after first dose</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_21" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects will receive AK119 plus AK112 via intravenously (IV) Q3W up to 2 years.|Subjects will receive AK119 and AK112 plus pemetrexed and carboplatin via intravenously (IV) Q3W up to 4 cycles. Afterward AK119 and AK112 plus pemetrexed will continue to be treated up to 2 years.|Subjects will receive AK112 monotherapy via intravenously (IV) Q3W up to 2 years.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: AK119; Drug: Pemetrexed; Drug: AK112; Drug: Carboplatin</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of subjects with dose limiting toxicities (DLTs)|Number of subjects with adverse events (AEs)|Objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR is defined as the proportion of subjects with confirmed CR or confirmed PR.; DLTs will be assessed during the first 3 weeks of treatment. DLTs are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug and unrelated to disease disease progression inter-current illness or concomitant medications that occurs within the DLT observation period.; AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF whether or not considered related to the study treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years; During the first 3 weeks; From the time of informed consent signed through 90 days after the last dose of study drug</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_22" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Part A will consist of dose escalation with KVA12123 administered as a single agent in participants with advanced solid tumors.|Part B will consist of dose escalation with KVA12123 administered in combination with a fixed dose of pembrolizumab.|Part C will consist of dose expansion with KVA12123 administered as a single agent at the RP2D in participants with advanced solid tumors.|Part D will consist of dose expansion with KVA12123 administered at the RP2D in combination with a fixed dose of pembrolizumab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: KVA12123 - Dose Expansion; Drug: KVA12123 Plus Pembrolizumab - Dose Escalation; Drug: KVA12123 Plus Pembrolizumab - Dose Expansion; Drug: KVA12123 - Dose Escalation</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Adverse Events|AEs related to study drug|Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Type and frequency of adverse events as assessed by CTCAE v4.0.; Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD) of KVA12123 when administered alone and in combination with pembrolizumab in participants with advanced solid tumors (milligrams or milligrams/kilogram).; Type and frequency of treatment related adverse events as assessed by CTCAE v4.0.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through study completion an average of 1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_23" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (1.4mg) administered via SC injection weekly for 4 consecutive weeks followed by bi-weekly injections over 4 weeks during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)|ELI-002 Amph-CpG-7909 (10.0mg) admixed with ELI-002 Amph-Peptides 7P (4.9mg) administered via SC injection weekly for 4 consecutive weeks followed by bi-weekly injections over 4 weeks during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)|The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks followed by bi-weekly injections over 4 weeks during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)|The ELI-002 7P dose selected during the Phase 1A portion of the study will be administered via SC injection weekly for 4 consecutive weeks followed by bi-weekly injections over 4 weeks during the Immunization Period; additional SC injections for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: ELI-002 7P</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1: Evaluate the safety of ELI-002 7P|Phase 2: Determine whether ELI-002 7P improves relapse-free survival (RFS) compared with Observation</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>RFS is assessed by the central imaging laboratory through computed tomography (CT) imaging or magnetic resonance imaging (MRI) with contrast and using iRECIST criteria; Safety will be assessed by the incidence of adverse events (AEs) and clinically significant changes in laboratory tests and vital signs</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>After the last radiographic assessment at Visit 23 (Week 106); 28 days after the first dose of ELI-002 7P</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_24" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients with colorectal cancer receive devimistat IV 5-FU IV plus HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.|Patients with pancreatic cancer receive devimistat IV 5-FU IV plus HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.|Patients with gastroesophageal cancer receive devimistat IV 5-FU IV plus HCQ PO on study. Patients with urothelial ovarian or non-small cell lung cancer receive devimistat IV gemcitabine IV plus HCQ PO on study. Patients with biliary tumors receive devimistat IV and gemcitabine IV or HCQ PO on study. Patients also undergo CT and/or MRI and undergo blood specimen collection throughout the study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Gemcitabine Hydrochloride; Procedure: Magnetic Resonance Imaging; Drug: Fluorouracil; Drug: Devimistat; Drug: Hydroxychloroquine; Procedure: Computed Tomography; Procedure: Biospecimen Collection</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 in patients with solid tumors treated under this protocol. ORR is defined as the percentage of patients with documented complete response (CR) plus the percentage of patients with documented partial response (PR). ORR will be reported with the corresponding exact confidence intervals.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Time from baseline to disease progression initiates subsequent anti-cancer therapy or 24 months (whichever occurs first)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_25" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose Escalation/Evaluation|MRTX1133 recommended Phase 2 dose administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12D mutation to include the following: NSCLC PDAC CRC Other Solid Tumors</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: MRTX1133</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1: Number of Patients who Experience Dose-Limiting Toxicity|Phase 1/1b: Number of patients who experience a treatment-related adverse event|Phase 2: Objective response rate (ORR)|Phase 2: Duration of response (DOR)|Phase 2: Progression free survival (PFS)|Phase 2: Overall survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years; 21 Days; Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_26" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Radiation + PBMC|Radiation + UCB</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Patients with a UCB donor; Biological: Patients with a living donor</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of treatment-related adverse events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Evaluation by follow-up clinic visits including medical questionnaire physical exam & blood tests: complete blood count electrolytes renal & liver function tests. AE will be graded using National Cancer Institute's Common Toxicity Criteria version 3 (7). Evaluations will take place twice a week for the first 2 weeks weekly for 2 weeks every 2 weeks for 2 months & every month for 3 months. It is anticipated that a maximum of 1 of 6 patients will have grade 3 side effects including nausea diarrhea dyspnea cough fever rash.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_27" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive carboplatin pemetrexed and paclitaxel by intravenous (IV) infusion.|Participants will receive zimberelimab monotherapy by IV infusion.|Participants will receive zimberelimab in combination with AB154 by IV infusion.|Participants will receive domvanalimab in combination with zimberelimab by IV infusion.|Participants will receive pembrolizumab by IV infusion.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Domvanalimab; Drug: Pemetrexed; Drug: Carboplatin; Drug: Zimberelimab; Drug: Paclitaxel; Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Arm D vs. Arm E</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From randomization until death from any cause (up to approximately 7 years)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_28" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>SBRT to all oligoprogressive sites</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Standard of care; Radiation: Sterotactic Body Radiotherapy/SBRT</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression Free Survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To study if the addition of early SBRT to extra-cranial oligo-progressive metastatic disease could prolong PFS compared to no SBRT. PFS is defined as the time from randomization to disease progression or death.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 52 weeks after final participant is enrolled</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_29" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Cohort 1: Patients with Non-Small Cell Lung Cancer with squamous cell or adenocarcinoma histology who have not been treated with a PD-1 or PD-L-1 blocking antibody (entinostat + pembrolizumab)|Cohort 2: Patients with NSCLC (any histology) who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)|Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)|Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: pembrolizumab; Drug: entinostat</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Participants taking 3mg entinostat weekly with Adverse Events as a Measure of Safety and Tolerability|Number of Participants taking 5mg entinostat weekly with Adverse Events as a Measure of Safety and Tolerability|Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 1 Stage 1 (NSCLC)|Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 2 Stage 1 (NSCLC pre-treated)|Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 1 (Melanoma pre-treated)|Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 1 Stage 2 (NSCLC)|Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 2 Stage 2 (NSCLC pre-treated)|Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 2 (Melanoma pre-treated)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>- Cohort 3 Stage 1: If enough patients achieve an objective response then enrollment will continue into the second stage.; Cohort 1 Stage 2: If enough patients achieve a CR or PR than the true ORR for the combination therapy.; - Cohort 2 Stage 1: If enough patients achieve an objective response then enrollment will continue into the second stage.; Ph 1 Dose Escalation - All patients within each dose escalation cohort are to complete C1 have safety assessments performed through C2D1 and be assessed for DLT before enrollment of the next cohort may commence.; - Cohort 2 Stage 2: IIf enough patients achieve a CR or PR than the true ORR for the combination therapy.; Measured by Overall Response Rate using irRECIST.; - Cohort 1 Stage 1: If enough patients achieve an objective response (CR or PR) enrollment will continue into the second stage.; - Cohort 3 Stage 2: If enough patients achieve a CR or PR than the true ORR for the combination therapy.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>In approximately 1 year; In approximately 2 years; In approximately 3-4 months after 3-6 patients have enrolled and been on study for 1 cycle; In approximately 6-8 months after 3-6 patients have enrolled and been on study for 1 cycle</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_30" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants with advanced solid tumors will receive escalating doses of ABBV-400.|Participants with c-Met intermediate/high advanced non-squamous wtEGFR NSCLC will receive ABBV-400 at the Recommended Phase 2 dose (RP2D).|Participants with c-Met intermediate/High advanced non-squamous mutEGFR NSCLC will receive ABBV-400 at RP2D.|Participants with c-Met low non-squamous wtEGFR NSCLC will receive ABBV-400 at RP2D.|Participants with squamous NSCLC will receive ABBV-400 at RP2D.|Participants with c-Met overexpressing Gastroesophageal adenocarcinoma will receive ABBV-400 at the RP2D.|Participants with c-Met unselected Colorectal Cancer; will receive ABBV-400 at the RP2D or Dose A.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: ABBV-400</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR defined as percentage of participants with confirmed best overall response of Confirmed complete response (CR) and partial response (PR) per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to Month 24</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_31" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Placebo; Drug: Tiragolumab; Drug: Atezolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR)|Progression Free Survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS defined as the time from randomization to the first occurrence of disease progression (PD) as determined by the investigator according to RECIST v1.1 or death from any cause whichever occurs first. PD: At least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum of diameters at prior timepoints (including baseline).; ORR defined as a complete response (CR) or partial response (PR) on two consecutive occasions /=4 weeks apart as determined by the investigator according to RECIST v1.1. CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions taking as reference the baseline sum of diameters in the absence of CR.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From baseline until a total of 80 progression free survival (PFS) events have occurred (up to approximately 11 months); From baseline until a total of 80 PFS events have occurred (up to approximately 11 months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_32" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive 18F-FSPG IV and undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days patients receive 18F-FDG IV and undergo a second PET/CT scan over 30-60 minutes.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Fludeoxyglucose F-18; Procedure: Positron Emission Tomography; Procedure: Computed Tomography; Drug: Fluorine F 18 L-glutamate Derivative BAY94-9392</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) specificity for malignant lung nodules</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>18F-FSPG accumulation in lung nodules will be assessed. The observed FSPG specificity will be assessed against a fixed value of 75%.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_33" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive docetaxel IV over 60 minutes ramucirumab IV over 60 minutes and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Ramucirumab; Biological: Pembrolizumab; Drug: Docetaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>6-month progression-free survival (PFS) rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will be determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be reported and its 95% confidence intervals will be estimated using the Clopper-Pearson method. PFS rates of two patient groups stratified by binary biomarker (PD-L1 and KRAS status) respectively will be estimated with the Kaplan-Meier method and compared using the log-rank test respectively. Cox proportional hazards models will be further used in the multivariable analyses to assess adjusted effect of PD-L1 and KRAS status on the patients' PFS after adjusting for other factors. Interaction terms between these factors will also be tested for statistical significance. The proportional hazards assumption will be evaluated graphically and analytically with regression diagnostics. Violations of the proportional hazards assumptions will be addressed by use of time-dependent covariates or extended Cox regression models.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_34" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>RADIATION THERAPY: Patients undergo hypofractionated radiation therapy 5 days per week for 3 weeks in the absence of disease progression or unacceptable toxicity.||CONSOLIDATION: Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for up to 12 months (maximum of 17 cycles) in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: Hypofractionated Radiation Therapy; Drug: Atezolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Rate of grade 3-5 adverse events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Individual toxicities with possible probable or likely attribution to treatment along with the overall rate of grade 3 4 or 5 toxicities attributable to treatment will be summarized.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From baseline until 180 days from Step 2 registration</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_35" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>In Part 1 (dose-escalation) participants will receive intravenous oleclumab (MEDI9447) Dose 1 every 2 weeks (Q2W) and oral osimertinib Dose 1 once daily (QD).|In Part 1 (dose-escalation) participants will receive intravenous oleclumab Dose 2 Q2W and oral osimertinib Dose 1 QD. In Part 2 (dose-expansion) participants (including participants dosed at the RP2D in Part 1) will receive IV oleclumab Dose 2 Q2W and oral osimertinib Dose 1 QD until documentation of disease progression intolerable toxicity or development of other reason for treatment discontinuation whichever occurs first.|In Part 1 (dose-escalation) participants will receive intravenous oleclumab Dose 1 Q2W and oral AZD4635 Dose 1 QD.|In Part 1 (dose-escalation) participants will receive intravenous oleclumab Dose 1 Q2W and oral AZD4635 Dose 2 QD.|In Part 1 (dose-escalation) participants will receive intravenous oleclumab Dose 2 Q2W and oral AZD4635 Dose 2 QD.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: AZD4635; Biological: Oleclumab; Drug: Osimertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Participants With Dose-limiting Toxicities (DLTs) in Part 1|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Parts 1 and 2|Number of Participants With Abnormal Laboratory Parameters Reported as TEAEs in Parts 1 and 2|Number of Participants With Abnormal Vital Signs and Physical Examination Reported as TEAEs in Parts 1 and 2|Number of Participants With Notable QTc Interval in Parts 1 and 2|Percentage of Participants With Objective Response (OR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in Part 2</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Notable QTc intervals included single beat changes from baseline (Day 1) values ( 30  60 and  90 milliseconds). Participants who had notable QTc interval are reported.; Participants with abnormal vital signs (heart rate blood pressure temperature and respiratory rate) and physical examination reported as TEAEs are reported.; A DLT was defined as = Grade 3 toxicity or adverse events (AE) occurred during DLT evaluation period which included any Grade 4 immune-mediated (immune nature) AE anemia thrombocytopenia (present  4 days) or neutropenia (present  4 days); = Grade 3 colitis or pneumonitis or interstitial lung disease (ILD); = Grade 3 nausea vomiting or diarrhea (not resolved to = Grade 2 in 3 days); Grade 2 pneumonitis or ILD (not resolved to = Grade 1 in 3 days); Grade 3 thrombocytopenia with bleeding any grade febrile neutropenia; convulsions seizures or stroke; protocol defined elevations of isolated liver transaminase isolated total bilirubin (TBL) or Hy's Law; confirmed QT interval corrected for heart rate by Fridericia's formula prolongation (= 501 msec) on triplicate electrocardiograms within a short period of time; or any other toxicity greater than that at baseline was clinically significant and/or unacceptable and was judged to be a DLT by the Dose Escalation Committee.; Participants with abnormal laboratory parameters reported as TEAEs are reported. Laboratory analysis included hematology clinical chemistry thyroid function tests and urinalysis.; The OR is defined as confirmed complete response (CR) or confirmed partial response (PR) based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target and non-target lesions no new lesions and normalization of tumor marker level. The PR is defined as = 30% decrease in the sum of the diameters of target lesions compared to baseline and non-progressive disease and not evaluable or no non-target lesion. A confirmed CR or PR is defined as 2 CRs or 2 PRs that were separated by at least 4 weeks with no evidence of progression in-between.; An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From Day 1 through 90 days of the last dose of study drug (approximately 37 months); From Day 1 to Day 28 after first dose of study drug</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_36" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Other</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>If you are assigned to this arm study doctors will sequentially remove and treat all visible cancer spots with surgery radiation ablation or other procedures. These interventions might include surgical removal of the diseased part of your lung liver lymph nodes and/or the lining of your belly. In addition if surgery could not be done we could treat these diseased spots with other modalities such as radiation and/or radiofrequency/microwave ablation.||If you're selected to be in this arm the type of procedure you receive will vary based on your cancer and what the study doctor recommends for treatment.|Participants in this arm receive the current standard of care chemotherapy for their specific type of gastrointestinal cancer. This treatment may include the continuation of chemotherapy and a few procedures which may improve your quality of life.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Lobectomy; Procedure: Video-Assisted Thoracic Surgery (VATS); Radiation: Consolidative Radiation; Procedure: Peritonectomy; Procedure: Resection or Excision; Other: Transarterial Radioembolization; Drug: Standard of Care Chemotherapy; Radiation: Ablation Treatment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression Free Survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The progression free survival (PFS) of participants undergoing sequential procedures (Arm A of study) vs standard of care chemotherapy (participants in Arm B - control group) as assessed by clinical records. Progression free survival will be defined as the time from randomization to first documented disease progression or death as assessed by clinical records.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_37" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>For the first two cycles Pembrolizumab will be administered at a predetermined dose every 3 weeks.|InVision plasma draw will take place at Cycle 1 Day 1 and Cycle 2 Day 1 with return of results to the treating oncologist prior to Cycle 3 Day 1.||At Cycle 3 patients will be re-registered per the inclusion criteria into 3 arms;||PEMBROLIZUMAB Alone|PEMBROLIZUMAB + Doublet Chemotherapy|- Following imaging assessment at Cycle 3 participants will continue pembrolizumab alone if the following responses are observed:||Response of Partial Response/Complete Response|Response of Stable Disease with plasma response|Response of Progressive Disease without worsening cancer symptoms AND plasma response|Following imaging assessment at Cycle 3 participants will receive pembrolizumab in combination with platinum doublet chemotherapy if they have a response of stable disease without plasma response OR no plasma response and response of progressive disease without worsening cancer systems. Platinum doublet should be histology-appropriate and will be given on-label per treating oncologist.|PEMBROLIZUMAB||Chemotherapy multiple agents systemic||PEMETREXED|CARBOPLATIN|PACLITAXEL</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Diagnostic Test: InVision; Drug: PEMETREXED; Drug: CARBOPLATIN; Drug: PACLITAXEL; Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>6-month Progression Free Survival rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Kaplan-Meier method</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6 Months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_38" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Sevoflurane + intravenous lidocaine|Sevoflurane|Propofol TIVA + intravenous lidocaine|Propofol TIVA</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Lidocaine IV; Drug: Sevoflurane; Drug: Propofol</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Comparison of disease free survival (DFS) with propofol-TIVA versus sevoflurane|Comparison of disease free survival (DFS) with lidocaine compared with no lidocaine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The study will collect endpoint data for each participant on time of disease progression. This will be used to compare disease free survival across arms.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Until 3 years from participant index surgery date</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_39" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Treatment Arm</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: SV-101</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Antitumor activity</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To assess the preliminary antitumor activity of SV-101 as measured by RECIST 1.1 and iRECIST</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>4-6 weeks after each treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_40" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>0.5 mg/kg IV every 3 weeks|1.0 mg/kg IV every 3 weeks|2.0 mg/kg IV every 3 weeks|3.0 mg/kg IV every 3 weeks|4.0 mg/kg IV every 3 weeks|3.0 mg/kg IV every 3 weeks|3.0 mg/kg IV every 3 weeks|3.0 mg/kg IV every 3 weeks|3.0 mg/kg IV every 3 weeks|3.0 mg/kg IV every 3 weeks|vobramitamab duocarmazine: Anti-B7-H3 antibody drug conjugate; retifanlimab: Anti-PD-1 antibody</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: retifanlimab; Biological: vobramitamab duocarmazine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of patients with Adverse Events of vobramitamab duocarmazine as assessed by CTCAE v4.03|Number of patients with dose limiting toxicities (DLT)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.; Maximum tolerated or maximum administered dose of vobramitamab duocarmazine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 42 days from first dose; Throughout the study up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_41" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Pyrotinib maleate tablet 400 mg once daily (QD)|Docetaxel injection 75 mg/m2 once every 3 weeks (Q3W)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Docetaxel; Drug: Pyrotinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Time from the date of randomization to the date of first disease progression documented by BIRC according to the RECIST v1.1 or death for any cause whichever comes first.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>26 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_42" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Drainage followed by nivolumab (40 mg single intrapleural instillation) will be performed.|Drainage followed by nivolumab (40 mg single intrapleural instillation) will be performed.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>3-month recurrence-free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Proportion of patients who will be without signs of radiographic recurrence after 3 months</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_43" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Phase 1:||Schedule A: Tinostamustine (EDO-S101) IV 60mg/m2 up to 100mg/m2 Day 1 and 15 of each 28 day cycle||Phase 2:||The RP2D and selected schedule will be further investigated in patients with specific types of solid tumors: relapsed/refractory SCLC soft tissue sarcoma triple negative breast cancer ovarian cancer and endometrial cancer.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Tinostamustine (EDO-S101)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety: Number of participants with treatment-related adverse events as assessed by CTCAE V4.03|Objective Response Rate (ORR) and SD that persists for at least 4 months in selected solid tumor cohorts</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Safety: Number of patients experiencing treatment-related adverse events as assessed by CTCAE v4.03.; ORR is defined as proportion of subjects with CR or PR based on RECIST V.1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12 months from beginning phase 1; 12 months from beginning phase 2</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_44" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive 18F-FMAU intravenously (IV) and undergo a PET/CT scan over 60 minutes. Patients then undergo standard of care mpMRI over approximately 45 minutes.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Procedure: Multiparametric Magnetic Resonance Imaging; Drug: 18F-FMAU; Procedure: Positron Emission Tomography; Procedure: Computed Tomography</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Correlation between multiparametric magnetic resonance imaging (mpMRI) radiomics and dynamic fluorine F 18 (18F)-FAMU (FMAU) positron emission tomography (PET) kinetic analysis parameters|Different pattern in radiomics mpMRI and FMAU PET kinetic analysis parameters</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>"Interesting patterns will be observed at individual subject level for the difference between presence or absence of recurrent tumor which defined as either underlying immunohistochemistry (Ki67-MIB proliferation marker when tissue sample is available or a binary proxy marker of subsequent clinical management decision (with wait-and-watch strategy for 1 month after imaging studies considered as ""absence"" of recurrent tumor otherwise marked as ""presence"" of recurrent tumor). Heatmap will be used with subject identification as x-axis and each radiomic/kinetic feature as y-axis. Features will be divided by categories to facilitate the visualization of patterns.; Scatter plots will be used to illustrate the pattern of correlation. For normality distributed data Pearson correlation will be used; otherwise Spearman correlation will be used. There will be 90 pairs of correlations. To further confirm the robustness of the correlation finding the Benjamini-Hochberg procedure will be applied to prevent false discovery."</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_45" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>PF-07248144 Monotherapy Escalation|PF-07248144 with Fulvestrant Combination Dose Escalation|PF-07248144 with Letrozole + Palbociclib Combination Dose Escalation|PF-07248144 Monotherapy Dose Expansion|PF-07248144 with Fulvestrant Dose Expansion|PF-07248144 with PF-07220060 +Fulvestrant|PF-07248144 with PF-07220060 +Fulvestrant Dose Expansion|PF-07248144 Monotherapy Dose Expansion</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Fulvestrant; Drug: PF-07220060; Drug: Palbociclib; Drug: PF-07248144; Drug: Letrozole</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with dose-limiting toxicities in the Dose Escalation Arms.|Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Escalation Arms.|Safety and Tolerability through monitoring of laboratory assessments for participants enrolled in the Dose Escalation Arms.|Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Expansion Arms|Safety and Tolerability through monitoring of laboratory assessments for participants enroled in the Dose Expansion Arms</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Dose-limiting toxicities (DLTs); Adverse Events as characterized by type frequency severity (as graded by NCI CTCAE version 5.0) timing seriousness and relationship to study therapy.; Laboratory abnormalities as characterized by type frequency severity (as graded by NCI CTCAE version 5.0) and timing.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 29 days; Up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_46" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each cycle (cycle length = 3 weeks) every 3 weeks (Q3W) up to 35 administrations (up to approximately 2 years) or until disease progression (PD) or discontinuation MK-4830 800 mg IV infusion on Day 1 of each cycle Q3W up to 35 administrations (up to approximately 2 years) or until PD or discontinuation; etoposide 100 mg/m^2 on Days 1 2 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m^2 or carboplatin AUC 5 mg/ml/min IV Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each cycle Q3W up to 35 administrations (up to approximately 2 years) or until PD or discontinuation MK-5890 30 mg IV infusion on Day 1 of each cycle (cycle length = 6 weeks) every 6 weeks (Q6W) up to 18 administrations (up to approximately 2 years) or until PD or discontinuation; etoposide 100 mg/m^2 on Days 1 2 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m^2 or carboplatin AUC 5 mg/ml/min IV Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.|Participants receive pembrolizumab 200 mg IV infusion on Day 1 of each 3 week cycle (Q3W) up to 35 administrations (up to approximately 2 years) or until PD or discontinuation lenvatinib 8 mg once daily (QD) orally up to Cycles 1-4 cycles and up to 20 mg QD orally for Cycles 5-31 or until PD or discontinuation; etoposide 100 mg/m^2 on Days 1 2 3 of each cycle for up to 4 cycles (up to approximately 12 weeks) and cisplatin 75 mg/m^2 or carboplatin AUC 5 mg/ml/min IV Day 1 of each cycle Q3W up to 4 cycles (up to approximately 12 weeks) or until PD or discontinuation.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Cisplatin; Drug: Etoposide; Biological: Pembrolizumab; Drug: Carboplatin; Drug: Lenvatinib; Biological: MK-4830; Biological: MK-5890</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)|Six-Month Progression-Free Survival (PFS) as Assessed by BICR per RECIST 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.; Six-month PFS is defined as the survival without documented disease progression (PD) per RECIST 1.1 by BICR or death due to any cause whichever occurs first at 6 months after randomization. PD is defined as 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20% the sum must also demonstrate an absolute increase of 5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 5 years; Up to approximately 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_47" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>CDK2 monotherapy dose escalation|CDK2 + palbociclib + fulvestrant|CDK2 + palbociclib + letrozole|PF-07104091 monotherapy dose expansion (SCLC)|PF-07104091 monotherapy dose expansion (ovarian)|PF-07104091 + fulvestrant (post CDK4/6) dose expansion|CDK2+ fulvestrant (post CDK 4/6) dose escalation</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: PF-07104091 monotherapy dose escalation; Drug: PF-07104091 + palbociclib + fulvestrant; Drug: PF-07104091 monotherapy dose expansion (SCLC); Drug: PF-07104091 + palbociclib + letrozole; Drug: PF-07104091 monotherapy dose expansion (ovarian); Drug: PF-0704091 + Fulvestrant (post CDK4/6); Drug: PF-07104091 + Fulvestrant (post CDK4/6)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle|To evaluate incidence of treatment emergent adverse events and laboratory abnormalities|Evaluate pulse rate that is out of normal range and changes in pulse rate as compared to baseline|Evaluate blood pressure that is out of normal range and changes in blood pressure as compared to baseline|To evaluate heart rate corrected QT interval and changes in corrected QT interval as compared to baseline|To evaluate the preliminary antitumor activity of PF-07104091 as a single agent and in combination with palbociclib and in combination with letrozole or fulvestrant or fulvestrant alone by objective response rate (ORR) in dose expansion</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of participants with DLTs which are typically Grade 3 or higher adverse events will be summarized by dose level; Identify pulse rate readings that are outside the normal range. The number and percentage of participants who experienced significant pulse rate change from baseline will be summarized by dose level; Identify systolic and diastolic readings that are outside the normal range. The number and percentage of participants who experienced significant blood pressure change from baseline will be summarized by dose level; Percentage of participants with a best overall response of complete response (CR) or partial response (PR) using RECIST 1.1; Determine the effect of the drug on QT prolongation. The number and percentage of participants who experienced QT interval prolongation will be summarized by dose level; Type incidence severity timing seriousness and relationship to study treatment of adverse events and any laboratory abnormalities will be summarized by dose level</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>28 days; From baseline through disease progression or study completion (approximately 2 years); From baseline until end of study treatment or study completion (approximately 2 years)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_48" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose Escalation and Backfill run concurrently|Dose Expansion is initiated after Dose Escalation and Backfill.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BAY2927088_formulation B_1; Drug: BAY2927088_formulation B_2; Drug: BAY2927088_formulation A</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with treatment-emergent adverse events (TEAEs)|Number of participants with treatment-emergent serious adverse events (TESAEs)|Severity of TEAEs|Severity of TESAEs|Number of participants who discontinue study treatment due to an AE|Maximum tolerated dose (MTD) or maximum administered dose (MAD) within the DLT observation period|Number of participants experiencing dose-limiting toxicities (DLTs) at each dose level associated with administration of BAY2927088|Cmax of BAY2927088|AUC(0-24) of BAY2927088 for QD|AUC(0-12) of BAY2927088 for BID|Cmaxmd of BAY2927088|AUC(0-24)md of BAY2927088 for QD|AUC(0-12)md of BAY2927088 for BID</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>If applicable AUC(0-12)md: AUC(0-12) after multiple dose administrations; AUC(0-24)md: AUC(0-24) after multiple dose administrations; If applicable. AUC(0-12): AUC from time 0 to 12 hours post dose. BID: Bis in die 2 times daily.; In Dose Escalation (including participants from Backfill); AUC: Area under the concentration vs. time curve. AUC(0-24): AUC from time 0 to 24 hours post dose. QD: Quaque die (once daily); Cmax: Maximum/peak concentration; Cmaxmd: Cmax after multiple dose administrations</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At the end of Cycle 1 of a 21-day cycle; Cycle 1 Day 1 (Cycle duration is 21 days); About 4 years (Up to the end of study treatment); Cycle 1 Day 15 (Cycle duration is 21 days); Up to 30 days after the last administration of study treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_49" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Durvalumab given in combination with olaparib .|Durvalumab given in combination with AZD9150.|Durvalumab given in combination with AZD6738.|Durvalumab given in combination with Vistusertib (AZD2014).|Durvalumab given in combination with Oleclumab|durvalumab given in combination with trastuzumab deruxtecan (DS-8201a)|durvalumab given in combination with cediranib (AZD2171)|AZD6738 (ceralasertib) given as monotherapy|durvalumab given in combination with AZD6738 (D15-D28)|durvalumab in combination with twice daily 160 mg or 240 mg AZD6738 (D22-D28)|AZD6738 (ceralasertib) monotherapy on D1-7 of every 28 days</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: AZD6738; Drug: trastuzumab deruxtecan; Drug: AZD6738 (ceralasertib) (240 mg or 160 mg); Drug: Vistusertib; Drug: Durvalumab; Drug: AZD6738 (ceralasertib); Drug: AZD6738 (ceralasertib) 7 days monotherapy; Drug: AZD9150; Drug: Olaparib; Drug: Oleclumab; Drug: cediranib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Assessment of the efficacy of each treatment by evaluation of objective response rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Endpoint based on Response Evaluation Criteria in Solid Tumours (RECIST 1.1); Objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_50" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Durvalumab monotherapy: Durvalumab (1500 mg intravenous [IV]) q4w in combination with placebo saline solution (IV) q4w for up to 4 doses/cycles each followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with placebo saline solution.|Durvalumab in combination with tremelimumab: Durvalumab (1500 mg IV) q4w in combination with tremelimumab (75 mg IV) q4w for up to 4 doses/cycles each followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with tremelimumab.|Placebo: Placebo saline solution (IV) q4w in combination with a second placebo saline solution (IV) q4w for up to 4 doses/cycles each followed by a single placebo saline solution q4w. The first placebo saline solution monotherapy dose q4w will be 4 weeks after the final dose of the 2 placebo saline solutions in combination.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Durvalumab; Other: Placebo; Drug: Tremelimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS)|Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To assess the efficacy of Durvalumab monotherapy vs Placebo in terms of PFS; To assess the efficacy of Durvalumab monotherapy vs Placebo in terms of OS</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately 6 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_51" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Pre-treated patients with cMET GCN  6 treated with INC280 at 400mg BID as second or third line|Pre-treated patients with cMET GCN  4 and  6 treated with INC280 at 400 mg BID as second or third line|Pre-treated patients with cMET GCN  4 treated with INC280 at 400mg BID as second or third line|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID as second or third line|Treatment-nave patients with cMET dysregulation treated with INC280 at 400mg BID|Pre-treated patients with cMET deregulation treated with INC280 at 400 mg BID as second line|Treatment-nave patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: INC280 (capmatinib)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Proportion of patients with a best overall response defined as complete response (CR) or partial response (PR) by Blinded Independent Review Committee (BIRC) assessment per RECIST 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>at least 18 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_52" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Other</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy|canakinumab matching-placebo in combination with pembrolizumab and platinum-based doublet chemotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: paclitaxel; Drug: cisplatin; Drug: pembrolizumab; Drug: pemetrexed; Drug: carboplatin; Drug: nab-paclitaxel; Drug: canakinumab; Drug: canakinumab matching placebo</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Safety run-in part: Incidence of dose limiting toxicities (DLTs)|Double-blind randomized placebo-controlled part: Progression free survival (PFS) per investigator assessment using RECIST v1.1|Double-blind randomized placebo-controlled part: Overall survival (OS) per investigator assessment using RECIST v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression free survival is defined as the time from randomization to the date of the first documented radiological progression using RECIST 1.1(Response evaluation criteria in solid tumor) or death due to any cause; Overall survival is defined as the time from date of randomization to date of death due to any cause; Incidence of DLTs assessed among at least 6 evaluable subjects during the first 42 days of study treatment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>38 months from start of randomization part; 18 months from start of randomization part; 6 months from start of safety run-in part</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_53" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Active Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive IV infusion of atezolizumab on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.|Participants will receive platinum-based chemotherapy consisting of a platinum agent (carboplatin or cisplatin) in combination with pemetrexed (non-squamous disease) OR gemcitabine or paclitaxel (squamous disease).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Cisplatin; Drug: Atezolizumab; Drug: Gemcitabine; Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-Free Survival (PFS) Assessed by Investigator</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression-free survival (PFS) assessed by investigator is defined as the time from randomization to the first occurrence of disease progression as determined by site investigator according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or death from any cause whichever occurs first.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Randomization to the first occurrence of disease progression or death from any cause whichever occurs first (up to approximately 28 months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_54" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>AMG 757 Monotherapy|AMG 757 with Pembrolizumab|AMG 757 with additional cytokine release syndrome (CRS) mitigation strategies|AMG 757 administration with 24-hour monitoring|AMG 757 administered in outpatient infusion centers with 8-hour monitoring||Optional wearable digital device substudy (US sites only)|AMG 757 additional dosing schedule||Optional wearable digital device substudy (US sites only)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: AMG 757; Drug: Pembrolizumab; Drug: CRS Mitigation Strategies</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with dose limiting toxicities (DLT) for all indications|Number of participants with treatment-emergent adverse events (AEs) for all indications|Number of participants with treatment-related AEs for all indications|Number of participants with clinically significant changes in vital signs for all indications|Number of participants with significant changes in ECG for all indications|Number of participants with significant changes in physical examinations for all indications|Number of participants with significant changes in clinical laboratory tests for all indications</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>24 months; 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_55" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Durvalumab monotherapy: Durvalumab (1500 mg intravenous [IV]) q4w in combination with placebo saline solution (IV) q4w for up to 4 doses/cycles each followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with placebo saline solution.|Durvalumab in combination with tremelimumab: Durvalumab (1500 mg IV) q4w in combination with tremelimumab (75 mg IV) q4w for up to 4 doses/cycles each followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with tremelimumab.|Placebo: Placebo saline solution (IV) q4w in combination with a second placebo saline solution (IV) q4w for up to 4 doses/cycles each followed by a single placebo saline solution q4w. The first placebo saline solution monotherapy dose q4w will be 4 weeks after the final dose of the 2 placebo saline solutions in combination.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Durvalumab; Other: Placebo; Drug: Tremelimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS)|Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To assess the efficacy of Durvalumab monotherapy vs Placebo in terms of PFS; To assess the efficacy of Durvalumab monotherapy vs Placebo in terms of OS</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Approximately 6 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_56" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>BI 765049|BI 765049 + ezabenlimab</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: ezabenlimab; Drug: BI 765049</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose (MTD) in any studied regimen|Number of patients with dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>defined as the highest dose with less than 25 percent (%) risk of the true dose limiting toxicity (DLT) rate being equal to or above 33 percent (%) during the MTD evaluation period</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 3 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IT ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_it">New Trials - Intratumoral</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Abdominal tumors</td>
    <td>Patrick Wagner MD FACS</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_57">Study Arms</button></td>
    <td>Lipopolysaccharide</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05751837" target="_blank">NCT05751837</a></td><td><select class="form-select" id="select_form_67" name="NCT05751837"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo4" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_57" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Injection of Lipopolysaccharide into one abdominal tumor</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Lipopolysaccharide</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The number nature and severity of adverse events as assessed by CTCAE v 4.0 will be determined in a series of six patients undergoing injection of bacterial-derived immunotherapeutic toll receptor agonist (LPS) instilled via direct injection into intra-abdominal tumors during laparoscopic surgery.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>30 Days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_it">Existing Trials - Intratumoral</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Metastatic Cancer; Solid Tumors</td>
    <td>Astellas Pharma Global Development Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_58">Study Arms</button></td>
    <td><p>ASP9801; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_529">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03954067" target="_blank">NCT03954067</a></td><td><select class="form-select" id="select_form_68" name="NCT03954067"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 182 days</strong></td>
    <td>Malignant peripheral nerve sheath tumor that cannot be removed by surgery (unresectable) or has come back after a period of improvement (recurrent)</td>
    <td>Mayo Clinic</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_59">Study Arms</button></td>
    <td>Computed Tomography; Laboratory Biomarker Analysis; Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter; Quality-of-Life Assessment; Single Photon Emission Computed Tomography</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02700230" target="_blank">NCT02700230</a></td><td><select class="form-select" id="select_form_69" name="NCT02700230"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo5" class="accordion-toggle">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo5"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 91 days</strong></td>
    <td>Advanced cancer (solid tumours)</td>
    <td>Boehringer Ingelheim</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_60">Study Arms</button></td>
    <td>BI 1387446; BI 754091</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04147234" target="_blank">NCT04147234</a></td><td><select class="form-select" id="select_form_70" name="NCT04147234"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_58" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive ASP9801 on days 1 and 15 of 28 day cycles to determine the recommended phase 2 dose. After cycle 2 participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles to determine the recommended phase 2 dose. After cycle 2 participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. After cycle 2 participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. After cycle 2 participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.|Participants will receive ASP9801 on days 1 8 15 and 22 of the first 28 day cycle. Participants will receive ASP9801 on days 1 and 15 on the second 28 day cycle at the dose recommended by the dose escalation phase. After cycle 2 participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. Participants will also receive pembrolizumab starting on day 1 and once every 6 weeks. After cycle 2 participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.|Participants will receive ASP9801 on days 1 8 15 and 22 of first 28 day cycle at the dose recommended by the dose escalation phase. Participants will also receive pembrolizumab starting on day 1 and once every 6 weeks. Participants will receive ASP9801 on days 1 and 15 on the second 28 day cycle at the dose recommended by the dose escalation phase. After cycle 2 participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. Participants will also receive pembrolizumab starting on day 1 and once every 6 weeks. After cycle 2 participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: ASP9801; Combination Product: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose Limiting Toxicities (DLT) - dose escalation part|Safety and tolerability assessed by Adverse Events (AEs)|Number of participants with laboratory value abnormalities and/or adverse events|Number of participants with vital sign abnormalities and /or adverse events|Safety assessed by 12- lead electrocardiograms (ECGs) adverse events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of participants with potentially clinically significant laboratory values.; Incidence of dose limiting toxicities; An AE is any untoward medical occurrence in a subject administered an investigational product (IP) and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding) symptom or disease (new or exacerbated) temporally associated with the use of IP whether or not considered related to the IP.; 12-lead ECGs will be read and assessed locally. Any clinically significant adverse changes on the ECG will be reported as Adverse Events.; Number of participants with potentially clinically significant vital sign values.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 12 months; Up to 28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_59" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive MV-NIS intratumorally on day 1. Patients also undergo SPECT/CT at baseline and at 3 and 8 days after MV-NIS. Patients may also undergo SPECT/CT at 15 and 28 days and at 6 weeks based on whether there is uptake on prior imaging studies.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Quality-of-Life Assessment; Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter; Other: Laboratory Biomarker Analysis; Procedure: Single Photon Emission Computed Tomography; Procedure: Computed Tomography</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Best response using the World Health Organization response criteria|Incidence of adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Maximum tolerated dose defined as the highest safely tolerated dose level where at most 1 out of 6 patients experience dose-limiting toxicity (DLT) with the next higher dose having at least 2 patients out of a maximum of 6 patients experience DLT</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population (overall and dose level).; The number and severity of all adverse events (overall and by dose-level) will be tabulated and summarized in this patient population. The grade 3+ adverse events will also be described and summarized in a similar fashion. Overall toxicity incidence as well as toxicity profiles by dose level patient and tumor site will be explored and summarized. Frequency distributions graphical techniques and other descriptive measures will form the basis of these analyses.; Assessed according to according to Common Terminology Criteria for Adverse Events version 4.0. The number and severity of all adverse events (overall and by dose-level) will be tabulated and summarized in this patient population.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years after treatment; 6 weeks; From the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started) assessed up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_60" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>superficial lesions|superficial lesions</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BI 1387446; Drug: BI 754091</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose (MTD) based on number of Dose-limiting toxicities (DLTs)|Number of patients with Dose limiting Toxicity (DLT) in the Maximum tolerated dose (MTD) evaluation period</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 weeks; up to 3 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW  CT ########### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_ct">New Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
<tr data-toggle="collapse" data-target="#demo6" class="accordion-toggle">  <td colspan="6"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo6"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Metastatic hormone-naive prostate cancer</td>
    <td>Janssen Research & Development LLC</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_61">Study Arms</button></td>
    <td><p>Abiraterone acetate; Prednisone; Androgen deprivation therapy (ADT); Abiraterone acetate Placebo; Prednisone Placebo</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_531">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01715285" target="_blank">NCT01715285</a></td><td><select class="form-select" id="select_form_71" name="NCT01715285"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_61" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive abiraterone acetate tablet at a total dose of 1000 milligram (mg) plus 5 mg capsule of prednisone orally once daily until disease progression withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) will be administered.|Participants will receive placebo matched to abiraterone acetate plus prednisone orally once daily until disease progression withdrawal of consent or unacceptable toxicity. Stable regimen of ADT will be administered.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Abiraterone acetate; Other: Androgen deprivation therapy (ADT); Drug: Abiraterone acetate Placebo; Drug: Prednisone; Drug: Prednisone Placebo</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Radiographic Progression-Free Survival (PFS)|Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Overall survival was defined as the time from randomization to date of death from any cause.; Radiographic PFS was defined as the time (in months) interval from randomization to the first date of radiographic progression or death. Radiographic progression included progression by bone scan (according to modified Prostate Cancer Working Group 2 [PCWG2] criteria) defined as at least 2 new lesions on bone scan and progression of soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI) (according to Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria). As per the RECIST 1.1 guideline progression requires a 20 percent (%) increase in the sum of diameters of all target lesions and a minimum absolute increase of 5 millimeter (mm) in the sum as compared to nadir sum of diameter.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 66 months; Up to 44 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING CT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ct">Existing Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 90 days</strong></td>
    <td>Desmoid tumors</td>
    <td>Children's Oncology Group</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_62">Study Arms</button></td>
    <td>Nirogacestat; Quality-of-Life Assessment; Questionnaire Administration</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04195399" target="_blank">NCT04195399</a></td><td><select class="form-select" id="select_form_72" name="NCT04195399"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Adenovirus CMV and EBV in subjects who have previously received any type of allogeneic HCT or solid organ transplant (SOT) or have compromised immunity</td>
    <td>Jessie L. Alexander</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_63">Study Arms</button></td>
    <td>Adenovirus Specific T- Lymphocytes; Cytomegalovirus Specific T-Lymphocytes; Epstein-Barr Virus Specific T-Lymphocytes</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04364178" target="_blank">NCT04364178</a></td><td><select class="form-select" id="select_form_73" name="NCT04364178"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Acute lymphoblastic leukemia</td>
    <td>University Hospital Tuebingen</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_64">Study Arms</button></td>
    <td>Tafasitamab</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05366218" target="_blank">NCT05366218</a></td><td><select class="form-select" id="select_form_74" name="NCT05366218"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Glioblastoma Multiforme</td>
    <td>Bryan Allen</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_65">Study Arms</button></td>
    <td><p>Ferumoxytol injection; Pharmacological ascorbate; External beam radiation therapy; Temozolomide</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_535">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04900792" target="_blank">NCT04900792</a></td><td><select class="form-select" id="select_form_75" name="NCT04900792"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 183 days</strong></td>
    <td>Newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL)</td>
    <td>Children's Oncology Group</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_66">Study Arms</button></td>
    <td><p>Allogeneic Hematopoietic Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Daunorubicin Hydrochloride; Dexamethasone; Dexrazoxane Hydrochloride; Doxorubicin; Etoposide; Filgrastim; Ifosfamide; Imatinib Mesylate; Laboratory Biomarker Analysis; Leucovorin Calcium; Mercaptopurine; Mercaptopurine; Methotrexate; Methylprednisolone; Pegaspargase; Prednisolone; Questionnaire Administration; Therapeutic Hydrocortisone; Thioguanine; Vincristine Sulfate</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_535">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03007147" target="_blank">NCT03007147</a></td><td><select class="form-select" id="select_form_76" name="NCT03007147"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 366 days</strong></td>
    <td>Rare genitourinary (GU) tumors</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_67">Study Arms</button></td>
    <td><p>Bone Scan; Cabozantinib S-malate; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_535">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03866382" target="_blank">NCT03866382</a></td><td><select class="form-select" id="select_form_77" name="NCT03866382"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Start Date pushed later by 120 days</strong></td>
    <td>Breast Cancer Female; Acute Leukemia; Lymphoma; Osteosarcoma; Soft Tissue Sarcoma; Ewing Sarcoma</td>
    <td>Kenny Rodriguez-Wallberg</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_68">Study Arms</button></td>
    <td><p>Triptorelin Embonate; Sodium Chloride solution 0.9%</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_535">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05328258" target="_blank">NCT05328258</a></td><td><select class="form-select" id="select_form_78" name="NCT05328258"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo7" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_62" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive nirogacestat PO BID on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nirogacestat; Other: Quality-of-Life Assessment; Other: Questionnaire Administration</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-free survival (PFS)|Incidence of adverse events|Pharmacokinetic (PK) parameter: systemic exposure|Pharmacokinetic (PK) parameter: drug clearance|Pharmacokinetic (PK) parameter: half-life</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. All grade 3 or above toxicities deemed related to study drug will be summarized. All grade 1 and 2 toxicities observed in  5% of participants and deemed related to study drug will be reported.; Will be estimated using the Kaplan-Meier method with the 95% confidence interval estimated by the Peto-Peto method.; PK parameters of nirogacestat will be defined to quantify systemic exposure drug clearance terminal half-life and other pharmacokinetic characteristics. These PK parameters will be summarized with descriptive statistics including means medians ranges and standard deviations.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From initiation of treatment to occurrence of disease progression or death from any cause assessed up to 2 years; Up to 2 years; Up to Cycle 3 (each cycle lasts 28 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_63" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy or CliniMACS Plus where they will be stimulated in vitro with viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system. By this method viral specific gamma-secreting T cells are captured in a closed sterile system.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Cytomegalovirus Specific T-Lymphocytes; Biological: Epstein-Barr Virus Specific T-Lymphocytes; Biological: Adenovirus Specific T- Lymphocytes</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Grade III-IV Acute Graft versus host disease|CTCAE Grade 4/5 Adverse Events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.; The incidence of patients who develop CTCAE Grade 4/5 Adverse events</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Day 0 through 90 days after last cellular infusion; Day 0 through 30 days from last cellular infusion</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_64" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>All patients will receive MOR00208 over 2-3 hours i.v. MOR00208 will be administered on a bi-weekly (every fourteen days) basis with infusions on Days 1 and 15 of each 28-day cycle. Additional doses will be administered on Day 4 Day 8 and Day 22 of Cycle 1 as well as Day 8 and Day 22 of Cycle 2 and Cycle 3.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Tafasitamab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Primary endpoint Part I|Primary endpoint Part II</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Determination of maximum tolerated dose of MOR00208 in pediatric patients; Time until hematological relapse ( 5% leukemic blasts) or increase of MRD  2 log in bone marrow during an observation time of 545 days accounting for competing risks</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>545 days; 49 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_65" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks.|Ferumoxytol: 512 g administered intravenously (IV) the day before radiation then at radiation treatments 6 25 and 31 ( 1 radiation treatment)|Radiation: 61.2 Gray (1.8 Gray / fraction / day) 5 days/week for approximately 8 weeks. T|Temozolomide: 75 mg/m2 taken orally once daily every day for 42 days or until radiation is completed (whichever comes first).|Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks.|Ferumoxytol: 512 g administered intravenously (IV) the day before radiation then at radiation treatment 25 ( 1 radiation treatment)|Radiation: 61.2 Gray (1.8 Gray / fraction / day) 5 days/week for approximately 8 weeks. T|Temozolomide: 75 mg/m2 taken orally once daily every day for 42 days or until radiation is completed (whichever comes first).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Ferumoxytol injection; Radiation: External beam radiation therapy; Drug: Pharmacological ascorbate; Drug: Temozolomide</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Determination of recommended phase 2 ferumoxytol dosing regimen</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The recommended dose will be determined by incidence of dose limiting toxicities.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From treatment day 1 through 12 weeks after completing radiation</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_66" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>See Detailed Description|See Detailed Description.|See Detailed Description</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Leucovorin Calcium; Drug: Ifosfamide; Drug: Cytarabine; Drug: Vincristine Sulfate; Drug: Pegaspargase; Drug: Daunorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Dexamethasone; Drug: Etoposide; Drug: Prednisolone; Drug: Methylprednisolone; Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Drug: Doxorubicin; Drug: Therapeutic Hydrocortisone; Drug: Cyclophosphamide; Biological: Filgrastim; Drug: Imatinib Mesylate; Drug: Methotrexate; Drug: Mercaptopurine; Drug: Dexrazoxane Hydrochloride; Drug: Thioguanine; Other: Questionnaire Administration</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Disease free survival (DFS) of Randomized Arms (standard risk [SR] Philadelphia chromosome [Ph+] acute lymphoblastic leukemia [ALL] patients)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Three-year DFS and 95% confidence intervals (CI) of SR Ph+ ALL patients treated continuous imatinib mesylate with high risk Children's Oncology Group (COG)-ALL chemotherapy backbone or more intensive European (Es)PhALL chemotherapy backbone.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_67" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive cabozantinib PO nivolumab IV and ipilimumab IV while on study. Patients undergo CT scan MRI PET and bone scans throughout the study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Nivolumab; Procedure: Magnetic Resonance Imaging; Procedure: Bone Scan; Biological: Ipilimumab; Procedure: Positron Emission Tomography; Drug: Cabozantinib S-malate; Procedure: Computed Tomography</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>An objective response is defined as a confirmed complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. A confirmed tumor response is defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Will be estimated by the number of confirmed objective responses divided by the total number of evaluable patients. Confidence intervals for the true ORR will be calculated.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_68" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Triptorelin given intramuscularly once every month or every third month during gonadotoxic chemotherapy treatment.||The dose is ether 11.25 mg triptorelin given for subjects having at least 3 months gonadotoxic treatment OR 3.75 mg for subjects during one-month of gonadotoxic treatment|Placebo 0.9% sodium chloride given intramuscularly once every month or every third month during gonadotoxic chemotherapy treatment.||The dose will be provided both as one injection compensating for 3 months' effect and one injection compensating for 1 month' effect to maintain the study blind.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Triptorelin Embonate; Drug: Sodium Chloride solution 0.9%</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Anti-Mllerian Hormone (AMH) levels in women with breast cancer</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To estimate the changes in ovarian reserve following chemotherapy for treatment of cancer with or without GnRHa by determination of the AMH relative to AMH levels at EoT in women with breast cancer.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12 months after end of gonadotoxic chemotherapy and study drug treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IA ############ -->
<!-- ############################### -->
<!-- ############################### -->

<h3 id="new_ia">NO NEW IMMUNE ACTIVATION TRIALS</h3><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IA ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ia">Existing Trials - Immune Activation</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 560 days</strong></td>
    <td>HIV-1-infection</td>
    <td>National Institute of Allergy and Infectious Diseases (NIAID)</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_69">Study Arms</button></td>
    <td>CVC 150 mg; CVC 300 mg; Placebo for CVC 150 mg; Placebo for CVC 300 mg</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05630885" target="_blank">NCT05630885</a></td><td><select class="form-select" id="select_form_79" name="NCT05630885"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo8" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_69" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Placebo Comparator</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants with pre-existing ART regimen of EFV will take CVC 300 mg. Participants with all other pre-existing ARTs will take CVC 150 mg.|Participants with pre-existing ART regimen of EFV will take placebo for CVC 300 mg. Participants with all other pre-existing ARTs will take placebo for CVC 150 mg.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Placebo for CVC 300 mg; Drug: CVC 300 mg; Drug: CVC 150 mg; Other: Placebo for CVC 150 mg</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Change in arterial most diseased segment (MDS) 18-FDG-PET target-to-background ratio (TBR) measured in the carotid arteries and aorta</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To assess whether CVC treatment results in reduced arterial inflammation by comparing the changes in arterial target-to-background ratio (TBR) in the carotid arteries and aorta after treatment with CVC versus placebo.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline Week 24</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## FDA APPROVALS ######## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="approvals">Drug Approvals/Applications</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Estrella Biopharma</td>
    <td>Estrella Biopharma Cleared by FDA to Begin Phase I/II Non-Hodgkin Lymphoma Trial</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/Starlight-1" target="_blank">Starlight-1</a></td><td><select class="form-select" id="select_form_80" name="Starlight-1"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo9" class="accordion-toggle" style = "background-color: #E1EBEE;">    <td>QSAM Biosciences</td>
    <td>QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/" target="_blank"></a></td><td><select class="form-select" id="select_form_81" name=""><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_500" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jan 15 2004' 'Jul 14 2003']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '50MG/5ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_505" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['3/8/2019' '5/18/2016']</td>
          <td>Intravenous</td>
          <td>['1200MG/20ML (60MG/ML)' '840MG/14ML (60MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_506" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jan 15 2004' 'Jul 14 2003']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '50MG/5ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '10MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>ETOPOSIDE</td>
          <td>VEPESID</td>
          <td>CORDEN PHARMA</td>
          <td>Nov 10 1983</td>
          <td>INJECTABLE;INJECTION</td>
          <td>20MG/ML</td>
            </tr>
            <tr>
          <td>ETOPOSIDE</td>
          <td>VEPESID</td>
          <td>STRIDES PHARMA</td>
          <td>Dec 30 1986</td>
          <td>CAPSULE;ORAL</td>
          <td>['50MG' '100MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_508" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jan 15 2004' 'Jul 14 2003']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '50MG/5ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_509" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jan 15 2004' 'Jul 14 2003']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '50MG/5ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_510" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jan 15 2004' 'Jul 14 2003']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '50MG/5ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '10MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['3/8/2019' '5/18/2016']</td>
          <td>Intravenous</td>
          <td>['1200MG/20ML (60MG/ML)' '840MG/14ML (60MG/ML)']</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_511" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>FULVESTRANT</td>
          <td>FASLODEX</td>
          <td>ASTRAZENECA</td>
          <td>Apr 25 2002</td>
          <td>INJECTABLE;INTRAMUSCULAR</td>
          <td>50MG/ML</td>
            </tr>
            <tr>
          <td>FULVESTRANT</td>
          <td>FULVESTRANT</td>
          <td>FRESENIUS KABI USA</td>
          <td>May 20 2019</td>
          <td>SOLUTION;INTRAMUSCULAR</td>
          <td>250MG/5ML (50MG/ML)</td>
            </tr>
            <tr>
          <td>FULVESTRANT</td>
          <td>FULVESTRANT</td>
          <td>TEVA PHARMS USA INC</td>
          <td>Aug 19 2019</td>
          <td>SOLUTION;INTRAMUSCULAR</td>
          <td>250MG/5ML (50MG/ML)</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_514" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_515" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>FLUOROURACIL</td>
          <td>ADRUCIL</td>
          <td>PHARMACIA AND UPJOHN</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>50MG/ML</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>CARAC</td>
          <td>VALEANT PHARMS NORTH</td>
          <td>Oct 27 2000</td>
          <td>CREAM;TOPICAL</td>
          <td>0.5%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>EFUDEX</td>
          <td>BAUSCH</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>['SOLUTION;TOPICAL' 'CREAM;TOPICAL']</td>
          <td>['5%' '2%']</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>FLUOROPLEX</td>
          <td>ALMIRALL</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>CREAM;TOPICAL</td>
          <td>1%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>FLUOROPLEX</td>
          <td>ELORAC</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>SOLUTION;TOPICAL</td>
          <td>1%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>FLUOROURACIL</td>
          <td>SPECTRUM PHARMS</td>
          <td>['Jul 29 2016' 'Approved Prior to Jan 1 1982']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['2.5GM/50ML (50MG/ML)' '500MG/10ML (50MG/ML)']</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>TOLAK</td>
          <td>HILL DERMACEUTICALS</td>
          <td>Sep 18 2015</td>
          <td>CREAM;TOPICAL</td>
          <td>4%</td>
            </tr>
            <tr>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>ACCORD HLTHCARE</td>
          <td>Aug 3 2017</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['200MG/2ML (100MG/ML)' '2GM/20ML (100MG/ML)' '1GM/10ML (100MG/ML)' '1.5GM/15ML (100MG/ML)']</td>
            </tr>
            <tr>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>HOSPIRA INC</td>
          <td>Aug 4 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['200MG/5.26ML (38MG/ML)' '1GM/26.3ML (38MG/ML)' '2GM/52.6ML (38MG/ML)']</td>
            </tr>
            <tr>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>GEMZAR</td>
          <td>LILLY</td>
          <td>May 15 1996</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['EQ 200MG BASE/VIAL' 'EQ 1GM BASE/VIAL']</td>
            </tr>
            <tr>
          <td>GEMCITABINE HYDROCHLORIDE</td>
          <td>INFUGEM</td>
          <td>SUN PHARM</td>
          <td>Jul 16 2018</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)' 'EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)' 'EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)' 'EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)' 'EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)' 'EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)' 'EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)' 'EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)' 'EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)' 'EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_517" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['50MG/VIAL' '150MG/VIAL' '450MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jan 15 2004' 'Jul 14 2003']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['600MG/60ML (10MG/ML)' '50MG/5ML (10MG/ML)' '150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '100MG/4ML (25MG/ML)' '500MG/20ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_518" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_519" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['3/8/2019' '5/18/2016']</td>
          <td>Intravenous</td>
          <td>['1200MG/20ML (60MG/ML)' '840MG/14ML (60MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_521" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>LIDOCAINE</td>
          <td>DENTIPATCH</td>
          <td>NOVEN</td>
          <td>May 21 1996</td>
          <td>['PATCH;TOPICAL' 'FILM EXTENDED RELEASE;BUCCAL']</td>
          <td>['23MG/PATCH' '46.1MG/PATCH']</td>
            </tr>
            <tr>
          <td>LIDOCAINE</td>
          <td>LIDODERM</td>
          <td>TEIKOKU PHARMA USA</td>
          <td>Mar 19 1999</td>
          <td>PATCH;TOPICAL</td>
          <td>5%</td>
            </tr>
            <tr>
          <td>LIDOCAINE</td>
          <td>XYLOCAINE</td>
          <td>ASTRAZENECA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>['SOLUTION;TOPICAL' 'SUPPOSITORY;RECTAL' 'AEROSOL;ORAL' 'OINTMENT;TOPICAL']</td>
          <td>['5%' '10%' '100MG']</td>
            </tr>
            <tr>
          <td>LIDOCAINE</td>
          <td>ZTLIDO</td>
          <td>SCILEX PHARMS INC</td>
          <td>Feb 28 2018</td>
          <td>PATCH;TOPICAL</td>
          <td>1.8%</td>
            </tr>
            <tr>
          <td>PROPOFOL</td>
          <td>DIPRIVAN</td>
          <td>FRESENIUS KABI USA</td>
          <td>['Oct 2 1989' 'Jun 11 1996']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>10MG/ML</td>
            </tr>
            <tr>
          <td>SEVOFLURANE</td>
          <td>ULTANE</td>
          <td>ABBVIE</td>
          <td>Jun 7 1995</td>
          <td>LIQUID;INHALATION</td>
          <td>100%</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_523" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['12/22/2014' '10/4/2017' '8/27/2021']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '120MG/12ML' '40MG/4ML' '100MG/10ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_525" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>FULVESTRANT</td>
          <td>FASLODEX</td>
          <td>ASTRAZENECA</td>
          <td>Apr 25 2002</td>
          <td>INJECTABLE;INTRAMUSCULAR</td>
          <td>50MG/ML</td>
            </tr>
            <tr>
          <td>FULVESTRANT</td>
          <td>FULVESTRANT</td>
          <td>FRESENIUS KABI USA</td>
          <td>May 20 2019</td>
          <td>SOLUTION;INTRAMUSCULAR</td>
          <td>250MG/5ML (50MG/ML)</td>
            </tr>
            <tr>
          <td>FULVESTRANT</td>
          <td>FULVESTRANT</td>
          <td>TEVA PHARMS USA INC</td>
          <td>Aug 19 2019</td>
          <td>SOLUTION;INTRAMUSCULAR</td>
          <td>250MG/5ML (50MG/ML)</td>
            </tr>
            <tr>
          <td>LETROZOLE</td>
          <td>FEMARA</td>
          <td>NOVARTIS PHARMS</td>
          <td>Jul 25 1997</td>
          <td>TABLET;ORAL</td>
          <td>2.5MG</td>
            </tr>
            <tr>
          <td>PALBOCICLIB</td>
          <td>IBRANCE</td>
          <td>PFIZER</td>
          <td>['Nov 1 2019' 'Feb 3 2015']</td>
          <td>['TABLET;ORAL' 'CAPSULE;ORAL']</td>
          <td>['125MG' '75MG' '100MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_526" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['500MG/10ML (50MG/ML)' '120MG/2.4ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_527" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['500MG/10ML (50MG/ML)' '120MG/2.4ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_529" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_531" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ABIRATERONE ACETATE</td>
          <td>YONSA</td>
          <td>SUN PHARM</td>
          <td>May 22 2018</td>
          <td>TABLET;ORAL</td>
          <td>125MG</td>
            </tr>
            <tr>
          <td>ABIRATERONE ACETATE</td>
          <td>ZYTIGA</td>
          <td>JANSSEN BIOTECH</td>
          <td>['Apr 28 2011' 'Apr 14 2017']</td>
          <td>TABLET;ORAL</td>
          <td>['500MG' '250MG']</td>
            </tr>
            <tr>
          <td>PREDNISONE</td>
          <td>DELTASONE</td>
          <td>PHARMACIA AND UPJOHN</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>TABLET;ORAL</td>
          <td>['20MG' '5MG' '10MG' '2.5MG' '50MG']</td>
            </tr>
            <tr>
          <td>PREDNISONE</td>
          <td>METICORTEN</td>
          <td>SCHERING</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>TABLET;ORAL</td>
          <td>['1MG' '5MG']</td>
            </tr>
            <tr>
          <td>PREDNISONE</td>
          <td>PARACORT</td>
          <td>PARKE DAVIS</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>TABLET;ORAL</td>
          <td>5MG</td>
            </tr>
            <tr>
          <td>PREDNISONE</td>
          <td>PREDNISONE</td>
          <td>ROXANE</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>TABLET;ORAL</td>
          <td>20MG</td>
            </tr>
            <tr>
          <td>PREDNISONE</td>
          <td>RAYOS</td>
          <td>HORIZON</td>
          <td>Jul 26 2012</td>
          <td>TABLET DELAYED RELEASE;ORAL</td>
          <td>['1MG' '2MG' '5MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_535" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</td>
          <td>HOSPIRA</td>
          <td>Oct 29 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>9MG/ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>BRONCHO SALINE</td>
          <td>BLAIREX</td>
          <td>Sep 3 1992</td>
          <td>AEROSOL METERED;INHALATION</td>
          <td>0.9%</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE</td>
          <td>ABBOTT</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>20GM/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE</td>
          <td>B BRAUN</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>20GM/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</td>
          <td>B BRAUN</td>
          <td>['Mar 9 1988' 'Approved Prior to Jan 1 1982']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>450MG/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</td>
          <td>BAXTER HLTHCARE</td>
          <td>['Feb 19 1982' 'Approved Prior to Jan 1 1982']</td>
          <td>['SOLUTION;IRRIGATION' 'INJECTABLE;INJECTION']</td>
          <td>450MG/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</td>
          <td>HOSPIRA</td>
          <td>['Jun 8 1988' 'Approved Prior to Jan 1 1982']</td>
          <td>['SOLUTION;IRRIGATION' 'INJECTABLE;INJECTION']</td>
          <td>450MG/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</td>
          <td>ICU MEDICAL INC</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>450MG/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</td>
          <td>MILES</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>450MG/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.9%</td>
          <td>B BRAUN</td>
          <td>Aug 11 2016</td>
          <td>INJECTABLE;INJECTION</td>
          <td>9MG/10ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.9%</td>
          <td>MEDEFIL INC</td>
          <td>Jan 6 2012</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['22.5MG/2.5ML (9MG/ML)' '18MG/2ML (9MG/ML)' '9MG/ML (9MG/ML)' '27MG/3ML (9MG/ML)' '90MG/10ML (9MG/ML)' '45MG/5ML (9MG/ML)']</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</td>
          <td>ABBOTT</td>
          <td>Jul 13 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>9MG/ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</td>
          <td>B BRAUN</td>
          <td>['Mar 9 1988' 'Approved Prior to Jan 1 1982']</td>
          <td>['SOLUTION;IRRIGATION' 'INJECTABLE;INJECTION']</td>
          <td>900MG/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</td>
          <td>BAXTER HLTHCARE</td>
          <td>['Dec 7 1992' 'Oct 30 1985' 'Approved Prior to Jan 1 1982']</td>
          <td>['SOLUTION;IRRIGATION' 'INJECTABLE;INJECTION']</td>
          <td>['900MG/100ML' '9MG/ML']</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</td>
          <td>HOSPIRA</td>
          <td>['Jul 15 1985' 'Oct 29 1982' 'Sep 17 1985']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['900MG/100ML' '9MG/ML']</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</td>
          <td>ICU MEDICAL INC</td>
          <td>['Jul 13 1984' 'Approved Prior to Jan 1 1982']</td>
          <td>['SOLUTION;IRRIGATION' 'INJECTABLE;INJECTION']</td>
          <td>['9MG/ML' '900MG/100ML']</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</td>
          <td>LIEBEL-FLARSHEIM</td>
          <td>Jul 27 2006</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['405MG/50ML (9MG/ML)' '1012.5MG/125ML (9MG/ML)']</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</td>
          <td>MILES</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>900MG/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER</td>
          <td>BAXTER HLTHCARE</td>
          <td>May 17 1985</td>
          <td>SOLUTION FOR SLUSH;IRRIGATION</td>
          <td>900MG/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 14.6%</td>
          <td>HOSPIRA</td>
          <td>Jul 20 1984</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['100MEQ/40ML (2.5MEQ/ML)' '50MEQ/20ML (2.5MEQ/ML)']</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 23.4%</td>
          <td>HOSPIRA</td>
          <td>Jun 18 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>400MEQ/100ML (4MEQ/ML)</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER</td>
          <td>ABRAXIS PHARM</td>
          <td>Apr 22 1987</td>
          <td>INJECTABLE;INJECTION</td>
          <td>234MG/ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 3% IN PLASTIC CONTAINER</td>
          <td>B BRAUN</td>
          <td>Mar 9 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>3GM/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 3% IN PLASTIC CONTAINER</td>
          <td>BAXTER HLTHCARE</td>
          <td>Nov 1 1983</td>
          <td>INJECTABLE;INJECTION</td>
          <td>3GM/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 5% IN PLASTIC CONTAINER</td>
          <td>B BRAUN</td>
          <td>Mar 9 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>5GM/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE 5% IN PLASTIC CONTAINER</td>
          <td>BAXTER HLTHCARE</td>
          <td>Nov 1 1983</td>
          <td>INJECTABLE;INJECTION</td>
          <td>5GM/100ML</td>
            </tr>
            <tr>
          <td>SODIUM CHLORIDE</td>
          <td>SODIUM CHLORIDE IN PLASTIC CONTAINER</td>
          <td>MILES</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>SOLUTION;IRRIGATION</td>
          <td>900MG/100ML</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<center><button type="submit" value="submit">Submit</button></center></div></form><br><p><strong> <em>Disclaimer: This weekly digest is a product created exclusively by Lexidyne LLC, in collaboration with Janssen. The intended purpose is to identify clinical phase assets with new data related to lung cancer, priority mechanisms of action, local/intratumoral delivery, and/or increased potency for acquisition & business development consideration. </em> </strong></p><p><em>Sources used include but are not limited to: PubMed, ClinicalTrials.gov, ASCO, AACR, NIH, EU Clinical Trials Register, European Pharmaceutical Review, FDA.gov, PRNewsWire, FiercePharma, and BioSpace. </em> </p><center><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSffyxD4xZGkc99oZTy9lF0xPdIaqUMfCVpI2lWJzBkH3uDEag/viewform" target="_blank">Subscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdaRqTScaPylLdbIIgAaWs3eYn3wMcF_qF408_-D9caWHAgLw/viewform" target="_blank">Unsubscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdSCfl2l2sV2jo-vFfym-VPpzyEs5M0cRRPY5TmBIZ-nR6gSQ/viewform" target="_blank">Feedback</a></div></center>
